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ABSTRACT 
Neuroblastoma (NB), a common cancer of childhood, contributes to 15% of 
all pediatric cancer deaths. The improper neuronal differentiation of neural 
crest cells to mature neurons in the sympathetic nervous system leads to NB 
tumor formation. NB is an extremely heterogeneous disease and high-risk NB 
is very difficult to treat, with the incidence of relapse in 50% of cases despite 
of intensive chemotherapeutic treatment. Long non-coding RNAs (lncRNAs) 
are a class of biological molecules that are transcribed but not translated to any 
functional protein. The mechanism of functions for these lncRNAs are diverse 
and context-specific. De-regulation of lncRNAs has been proposed to play a 
critical role in cancer development and progression. The goal of the current 
thesis was to identify novel neuroblastoma-specific lncRNAs for better 
stratification of the disease and characterizing their functional role in greater 
details.  
In the first study, we characterized differentially expressed lncRNAs between 
low-risk and high-risk NB tumors using transcriptome profiling. Among the 
differentially expressed lncRNAs, we chose a lncRNA, neuroblastoma 
associated transcript 1 (NBAT1), that maps to NB hotspot locus 6p22, which 
has been shown to harbor several NB-specific risk-associated SNPs. We 
showed that NBAT1 is a tumor suppressor lncRNA and it carries out this tumor 
suppressor function through regulating cellular proliferation and 
differentiation. Consistent with its tumor suppressor properties, its higher 
expression in NB patients predicts a good prognosis. Mechanistically, NBAT1 
controls NB cell growth through epigenetically silencing cell proliferating 
 genes, as well as NB cell differentiation by repressing the neuron-restrictive 
silencer factor NRSF, also known as REST.  
In the second study, we sought to investigate the functional connection 
between NBAT1 and its sense partner CASC15 lncRNA in NB development 
and progression. Like NBAT1, CASC15 harbors NB-specific tumor suppressor 
properties and its higher expression in NB patients correlates with good clinical 
outcomes. We show that CASC15/NBAT1 (6p22lncRNAs) promote cell 
differentiation by the specific regulatory interactions with SOX9 and USP36 
located on 17q, which is frequently gained in NB. We could show 
mechanistically that 6p22lncRNAs dictate SOX9 expression by controlling 
CHD7 stability via modulating cellular localization of USP36, which is a 
deubiquitinase.  
In the third and final study, we found that NBAT1 is a p53 responsive 
lncRNA and regulates p53 subcellular localization. We observed that a 
decrease in NBAT1 expression in NB cells results in resistance to genotoxic 
drugs, which in part occurs due to cytoplasmic p53 accumulation and 
concomitant loss of p53 dependent gene expression. Higher expression of the 
p53 exporter CRM1 in NBAT1 depleted cells contributes to p53 cytoplasmic 
localization, while CRM1 inhibition in these cells restores p53 localization. 
We observed that combined inhibition of CRM1 and MDM2 sensitized 
aggressive NB cells with cytoplasmic p53, suggesting that this drug 
combination could be a potential therapeutic strategy for high-risk NB patients.  
 
In summary, these findings highlight the regulatory role of lncRNAs in NB 
disease development. 
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SAMMANFATTNING PÅ SVENSKA 
Neuroblastom (NB), en vanlig cancer i barndomen, bidrar till 15% av 
barnmortalitet från cancer. Felaktig neuronal differentiering av neurallist  
celler till mogna nervceller i det sympatiska nervsystemet leder till NB-
tumörbildning. NB är en extremt heterogen sjukdom och högrisk NB är mycket 
svår att behandla, med förekomst av återfall i 50% av fallen trots intensiv 
kemoterapeutisk behandling. Långa icke-kodande RNA (lncRNA) är en klass 
av biologiska molekyler som transkriberas men inte översätts till något 
funktionellt protein. Funktionsmekanismerna för dessa lncRNA är 
mångfaldiga och kontextspecifika. Avreglering av lncRNA har föreslagits 
spela en kritisk roll i cancerutveckling och progression. Målet med den aktuella 
avhandlingen var att identifiera nya neuroblastom-specifika lncRNA för bättre 
stratifiering av sjukdomen och karakterisera deras funktionella roll mer 
detaljerat. 
I den första studien har vi karaktäriserat differentiellt uttryckta lncRNA mellan 
lågrisk- och högrisk NB-tumörer med hjälp av transkriptom profilering. Bland 
de differentiellt uttryckta lncRNA har vi valt ett lncRNA, neuroblastoma 
ssocierat transkript 1 (NBAT1), som ligger i NB hotspot locus, 6p22, som har 
visat sig innehålla flera NB-specifika riskassocierade SNP. Vi har visat att 
NBAT1 är en tumörsuppressor lncRNA och den utför denna tumörsuppressor 
funktion genom att reglera cell proliferation och differentiering. I 
överensstämmelse med dess tumörsuppressor egenskaper förutspår dess högre 
uttryck hos NB-patienter god prognos. Mekaniskt kontrollerar NBAT1 NB-cell 
proliferation genom epigenetiskt tystande cell proliferationsgener, och NB-cell 
differentiering genom att hämma den neuron-restriktiv tystnadsfaktorn NRSF, 
även känd som REST. 
I den andra studien eftersträvade vi att undersöka den funktionella kopplingen 
mellan NBAT1 och dess senspartner CASC15 lncRNA i NB-utveckling och 
progression. Liksom NBAT1, har CASC15 NB-specifika tumörsuppressor 
egenskaper och dess högre uttryck hos NB-patienter korrelerar med ett bra 
kliniskt utfall. Vi visar att CASC15 / NBAT1 (6p22 lncRNA) främjar cell 
differentiering genom specifika reglerande interaktioner med SOX9 och 
USP36 lokaliserade på 17q, vilken ofta tilltar i NB. Vi kunde visa mekanistiskt 
att 6p22 lncRNA dikterar SOX9-uttryck genom att kontrollera CHD7-stabilitet 
via modulering av cellulär lokalisering av USP36, som är ett deubikitinas. 
I den tredje och sista studien fann vi att NBAT1 är ett p53-responsivt lncRNA 
och reglerar den subcellulära lokaliseringen av p53. Vi observerade att en 
 minskning av NBAT1-uttryck i NB-celler resulterar i resistens mot genotoxiska 
läkemedel, som delvis inträffar på grund av cytoplasmisk p53-ansamling och 
samtidig förlust av p53-beroende genuttryck. Högre expression av p53-
exportör CRM1 i NBAT1-reducerade celler, bidrar till p53-cytoplasmisk 
lokalisering medan CRM1-hämning i dessa celler återställer p53 nukleär 
lokalisering. Vi observerade att en kombinerad hämning av CRM1 och 
MDM2, sensibiliserade aggressiva NB-celler med cytoplasmisk p53, vilket 
tyder på att denna läkemedelskombination kan vara en potentiell terapeutisk 
strategi för högrisk NB-patienter. 
Sammanfattningsvis belyser dessa fynd den reglerande rollen för lncRNA i 
NB-sjukdomens utveckling. 
Nyckelord: Neuroblastoma, långa icke-kodande RNA, NBAT1, NRSF / REST, 
CASC15, kromosom 6p22, SOX9, USP36, CHD7, p53, CRM1, MDM2. 
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1 INTRODUCTION 
1.1 Neuroblastoma 
Neuroblastoma (NB) is the most commonly diagnosed malignancy in the first 
years of life. The appearance of the neural crest derived NB tumors of the 
sympathetic nervous system is due to improper neuronal differentiation and 
causes 15 % of all childhood cancer mortality (1-3). Around 90 % of NB 
tumors are diagnosed by 5 years age of children with a median diagnosis age 
of 22 months (4, 5). NB is an extra cranial solid tumor that commonly occurs 
in adrenal medulla but can form in other places where sympathetic nervous 
tissue is present including paraspinal sympathetic ganglia in the chest, 
abdominal tissue, neck region, and liver (6-8). Many contributing parameters 
like the age of the patient, histology of the tumor, stage of the disease, DNA 
ploidy, chromosomal alteration, status of the MYCN oncogene and also NB 
tumor differentiation status are used for predicting disease outcome and 
treatment (9). Depending on the clinical stratification, NB tumors have been 
classified in several different risk-categories. For risk assessment the 
International NB Staging System (INSS) took the initiative to stage NB in a 
detailed manner and the main five stages are stage 1, stage 2 (A&B), stage 3, 
stage 4 & 4S. Stage 1 and 2 are designated as an early stage, which is generally 
localized, non-metastatic tumors and responds to radiation and chemotherapy. 
On the other hand stage 3 and 4 are designated as high-risk or advanced stage 
NB tumors with metastatic behavior and that are often resistant to 
chemotherapy treatment. Stage 4S is the 5th category of NB tumors where 
patients go through spontaneous regression of NB tumors without treatment 
(1, 3, 10-12).  In a broader sense, NB tumors are divided into three risk groups 
(low, intermediate and high-risk)  based on age, histology and MYCN status 
(10).  
 
1.1.1 Historical background of neuroblastoma 
NB was first described by the German physician Rudolf Virchow in 1864 and 
he classified the tumors he found in the abdomen of children as a glioma (13). 
In 1891, Felix Marchand first observed the features of the developing tumors 
in the sympathetic nervous system of an adrenal medulla that lies over the 
kidneys (14, 15). NB was again characterized by William Pepper in 1901, as it 
is prone to liver metastasis compared to bone metastasis in children (16). In 
1910, James Homer Wright illustrated these tumors as a collection of an 
immature, primitive form of undifferentiated nerve cells which are  neurocytes 
or neuroblasts and for this reason he named the tumors as neurocytoma or 
neuroblastoma (17). Wright also noted  the round clumps of cells  that formed 
Understanding the role of long non-coding RNAs in neuroblastoma development and 
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in bone marrow and these are now commonly referred to as "HomerWright 
pseudorosettes" (17). In 1927, Cushing and Wolbach described that not all NBs 
were metastatic. Some tumors were classified as malignant and they spread 
rapidly to various organs in the body like liver, skin, bone and bone marrow, 
other tumors resolved by themselves without treatment (18). Ganglioneuromas 
are a rare kind of tumor that turned into a non-malignant masses, which may 
spontaneously regress and this transformation from cancerous to noncancerous 
form is rare in babies over 6 months of age (14, 19). In 1957, Mason noted the 
risk assessment marker cathecholamines, which is a hormone and produced in 
high quantities by the high-risk NB tumors. The presence of the malignancy 
can be detected by encountering the presence of catecholamines in the urine of 
children with NB (20).  
 
1.1.2 Genetic alterations and chromosomal 
aberrations in neuroblastoma 
High-risk tumors are highly aggressive and harbor a variety of non-random 
chromosomal alterations such as the MYCN oncogene amplification, 1p, 11q 
deletion, 17q gain etc (21). The high-risk tumors have a high chance of 
recurrence, even after treatment with the most intensive multimodal therapies 
and show an unfavorable outcome. Low-risk NB tumors are associated with 
hyperploidy or whole chromosomal aberration and they are prognostically 
favorable and have a high chance of regression (22, 23). Besides the 
chromosomal alterations, some NB are associated with a number of recurrent 
point mutations in the kinase domain of ALK (Anaplastic   Lymphoma Kinase) 
receptor tyrosine kinase gene locus, which is centromeric to the MYCN locus 
(24, 25). Another prognostic marker of NB has been shown in many studies, is 
neurotrophin receptors that recognize neurotrophins (hormone-like chemicals 
that help nerve cells maturation). NB with more neurotrophin receptors 
especially the nerve growth factor called TrkA, has a better prognosis (26, 27). 
Tumor cell ploidy 
Tumor cell ploidy (DNA index) serves as a strong and important prognostic 
marker for NB patients. Hyperdiploid DNA content generally correlates with 
less aggressive lower stage and MYCN non-amplified tumors with favorable 
disease behavior.  Near-diploid (and near-tetraploid) tumors tend to correlate 
with more aggressive malignant tumors. Patients who are younger than one 
year old are more suitable for prediction of this correlation but it is not 
significant for patients who are 18 to 24 months of age of patients (28, 29). 
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MYCN amplification  
Currently amplification of the MYCN gene on chromosome 2p24 remains the 
best- characterized genetic marker to stratify risk in NB. In 1983, MYCN was 
first identified in human NB which is homologous to v-myc and distinc from 
the MYC gene (30, 31). Amplification of the MYCN gene accounts for 
approximately 20-30 % of all NB cases and possesses a strong correlation with 
poor prognosis in NB patients (1, 3, 22, 32, 33). Around 50 % of NB patients 
diagnosed with metastasis (3) with a significant spread to bone marrow (70%), 
bone (55%), lymph nodes (30%), liver (30%), and brain (18%) (34). This 
invasive and metastatic behaviour of NB cells correlates with the MYCN gene 
amplification and expression (35, 36). MYCN acts as a master regulator that 
involves numerous cellular processes and contributes to the different hallmarks 
of cancers. MYCN contributes to sustaining growth by promoting proliferation 
and cell cycle progression, for example, MYCN-amplified NBs failed to arrest 
in G1-phase in response to DNA damage via TP53 inducible nuclear protein 1 
(TP53INP1) downregulation (37-39). MYCN represses genes which leads to 
differentiation of NB cells (40). MYCN also promotes maintaining a stem-like 
state of self-renewal by blocking the differentiation pathway and promoting 
the expression of  pluripotency factors (41). MYCN also is shown to be 
involved in reprogramming fibroblasts into iPS cells, substituting MYC (42). 
MYCN can also regulate apoptosis and angiogenesis (43). MYCN is 
overexpressed in other cancers like glioblastoma, retinoblastoma and small cell 
lung carcinoma (SCLC) as in NB (44-46). To understand NB tumorigenesis, 
several MYCN transgenic mice have been developed, as overexpression of 
MYCN contributes to tumor progression interacting with other oncogenes 
partners (47, 48). 
1p deletion 
Segmental chromosomal loss of the distal short arm of chromosome 1 (1p) 
accounts for 25-35 % of NB tumors (1-3). 1p loss usually correlates with 
MYCN amplification and poor patient survival (10). Bader and colleagues 
investigated the importance of chromosome 1 in NB by transferring the normal 
portions of chromosome 1 short arm (1p) into the NB cell line. This 1p transfer 
to the NB cell line led to the differentiation and suppression of proliferation 
and tumorigenicity (49). The association of the loss of 1p chromosome with 
high-risk NB can be justified by the presence of tumor suppressor genes in this 
region. Several tumor suppressor genes CHD5, CAMTA1, KIF1B, CASZ1 and 
mir-34A have been identified in the 1p-deleted region. Introduction of CHD5, 
CAMTA1, KIF1B and mir-34A genes were able to reduce cell proliferation and 
led to apoptosis (50, 51). 
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11q deletion  
Loss of the long arm of chromosome 11 (11q deletion) is another frequent 
chromosomal alteration, noticed in high-risk NB and it accounts for 30-40 % 
of NB tumors (10). Interestingly this is inversely correlated with MYCN 
amplification (52). 11q deletion is associated with poor prognosis and 
decreased probable survival ability in NB patients (10). Transfer of 
chromosome 11 to the NB cell line also can induce differentiation, similar to 
chromosome 1 (49). Several tumor suppressor genes are located in this region, 
for example, immunoglobulin superfamily 4 (IGFSF4), a tumor suppressor in 
lung cancer/cell adhesion molecule 1 (TSLC1/ CADM1) (53, 54). TSLC1 gene 
transfer into TSLC1 low expressed NB, leads to reduced proliferation of NB 
cells (54). 
17q gain  
Another important chromosomal alteration in NB is the gain of the distal part 
of chromosomal arm 17q. 17q gain is associated with stage 4 metastatic NB 
significantly and it accounts for 40-50 % of NB patients which is more frequent 
than 1p deletion, 11q deletion and MYCN amplification (10). The gain of 17q 
correlates with MYCN amplification and leads to poor prognosis of NB 
patients (1, 3, 10, 55). Genes like PPMID, Survivin, NM23A are located in this 
region (10). Survivin, which is an apoptotic inhibitor correlates with the 
unfavourable outcome and its frequent overexpression has been observed in 
NB patients (10, 56). Another gene SOX9 is also located in 17q region and 
SOX9 overexpression has been shown to perturb differentiation in NB cells 
and the knocking down of SOX9 can rescue the differentiation phenotype 
which suggests 17q gain associated with SOX9 overexpression and poor 
outcome in NB (57). 
Anaplastic Lymphoma Kinase (ALK) amplification - cause for 
both sporadic and familial neuroblastoma 
Hereditary predisposition in NB is rare, found in 1-2 % of NB cases. ALK acts 
as a predisposition gene for NBs (25, 58). Amplification  of an ALK gene can 
promote ALK activation and correlates with the poor survival of the NB 
patients (59, 60). Other than amplification or overexpression of an ALK gene, 
point mutations in ALK have also been observed in both familial and sporadic 
NB patients (24, 25, 58, 61). ALK has been previously considered as an orphan 
receptor, but a recent study shows ALK has more than two ligands, heparin 
and members of the FAM150 protein family (62, 63).  ALK and MYCN can be 
co-amplified in high-risk NB as they share  similar locations on 2p (64). ALK 
expression is limited to neural tissues. In one mouse model (controlled by the 
dopamine β-hydroxylase (Dbh) promoter), it has been shown that gain-of-
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function mutation in ALK leads to NB tumor formation but requires constant 
co-expression of MYCN (using the tyrosine hydroxylase (TH) promoter) and 
this observation has also been validated in a Zebrafish model (48, 64). This co-
operation of ALK and MYCN can be explained due to ALK-mediated activation 
of phosphoinositide 3-kinase (PI3K) signaling (48, 64). Most of the point 
mutations of an ALK gene are reported within the ALK kinase domain and 
occurred in 7-9 % of NB patients (65). The two most frequently observed hot-
spot mutations in the ALK kinase domain are mutations in ALK-F1174 and 
ALK-R1275, which account for 70-80 % of all mutant cases (24, 25, 58, 61). 
It has been reported recently that activating ALK point mutations (F1174L/S, 
R1275, Y1278S and L1196M) is frequently observed in 30-40 % of relapsed 
NB cases and determines the sensitivity towards ALK inhibitors (66-68). 
Transient siRNA knockdown or inhibition of ALK in NB cells leads to 
decreased cell proliferation (25, 69). Targeting ALK and its downstream target 
can be a therapeutic strategy for ALK-positive NB patients. 
PHOX2B – a hereditary predisposition in neuroblastoma 
PHOX2B (which encodes paired mesoderm homeobox protein 2B and is a 
master regulator of neural crest development) has been identified as a first 
bonafide gene that can predispose in NB while mutated with a single copy in 
the germline (70, 71). This germline mutation of the PHOX2B gene could 
highlight the complex genetics of NB.  
The PHOX2B gene can regulate autonomic nervous system development (72) 
and children with congenital central hypoventilation syndrome (CCHS) which 
has a neural crest origin, are more prone to get specific mutation and 
neuroblastic tumor development (73, 74). Interestingly PHOX2B  has been 
shown as a key regulator of NB differentiation and stemness maintenance. A 
higher PHOX2B expression level correlates with NB cell proliferation and 
self-renewal and retinoic acid-induced neuronal differentiation can 
downregulate PHOX2B expression and thereby  can inhibit tumorigenicity by 
suppressing the self-renewal capacity of NB cells (75).  
Additionally, PHOX2B mutations also account for about 2% of sporadic NB 
patients (76). Together this indicates that PHOX2B might serve as a potential 
therapeutic target in NB patients. 
Other genomic rearrangements 
Using high throughput whole-genome sequencing,  genomic survey of NB 
tumors reveals a loss of function genetic alteration of ATRX (encoding the 
RNA helicase) in approximately 10% of patients, promoter rearrangement of 
TERT (encoding telomerase reverse transcriptase) which promotes enhancer 
hijacking, in approximately 25 % of NB tumors approximately (77, 78). 
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Amplification of LIN28B occurs rarely in NB but overexpression of 
polymorphic alleles within the LIN28B (encoding lin-28 homolog B) locus was 
identified to have a strong association with high-risk NB (79). In NB cells and 
mice (under the control of the Dbh promoter), LIN28B  misexpression leads to 
the accumulation of high levels of N-MYC and poor prognosis (80). Moreover, 
other amplifications and focal gain show enrichment of other target genes of 
N-MYC (81). 
1.1.3 Neuroblastoma and genome-wide association 
studies (GWAS) 
Over the last 10 years, genome-wide association studies (GWAS) have evolved 
into a convenient tool for investigating the structure of common human genetic 
variation or the overall genetic architecture of  human disease. GWAS studies 
revealed NB is associated with common polymorphic alleles that provide 
complexity to the disease. 12 highly significant genetic associations have been 
identified and validated to date (82). Though each association consists of 
moderate individual effect to initiate a disease, there is also a possible 
cooperation of multiple associations in an individual patient which can 
promote malignant transformation during neurodevelopment (83). Many 
GWAS associated NB susceptibility genes have been shown to act as a 
potential oncogene or tumor- suppressive gene in a disease context (84). Barr 
EK et al described the identifications of GWAS associated genes in a detailed 
manner (83), which I will briefly discuss in this thesis (Figure 1). 
In 2008, the first successful GWAS in NB was conducted using 464,934 
single-nucleotide polymorphisms (SNPs) and a cohort, where 1032 NB 
patients compared with 2043 healthy controls of European descent (85). 
Interestingly three variants on chromosome 6p22 were identified by this study, 
which mapped to the long non-coding RNAs (lncRNAs) NBAT1 (CASC14) 
and CASC15. The most statistically significant SNP was rs6939340, which 
shows strong association with MYCN amplified or stage 4 NB tumors. It has 
also been shown decreased expression of NBAT1 correlates with poor survival, 
cell proliferation and tumor growth (86). The sense-antisense lincRNA pair - 
NBAT1 and CASC15, harboring the disease-associated SNP rs6939340 have 
been mechanistically investigated to understand the significance of this genetic 
predisposition. By modulating the Ubiquitin-Specific Protease 36 (USP36) 
localization, decreased expression of CASC15 and NBAT1 leads to the stability 
of CHD7, a chromatin remodeler. CHD7 maintain an un-differentiated cellular 
state by inducing SOX9 expression and leads to NB tumor formation (57). 
Hence, trait associated lncRNAs NBAT1 and CASC15 act as tumor suppressor 
lncRNAs in NB development and can be considered using for NB risk 
assessment. 
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The next GWAS analysis conducted with the same cohort but using only 397 
high-risk patients from the original 1032 patient cohort, who were compared 
to the same 2043 healthy controls (87). Several new risk SNPs were identified 
on chromosome 2q35,which were located in the intronic region of  the BARD1 
gene, moreover, this risk SNPs were validated in an independent Italian cohort 
as well (88). BARD1 isoforms have high oncogenic activity and it can lead to 
neoplastic transformation of mouse fibroblasts (89). Additionally, BARD1 
interacts with AURKA, which actively stabilizes MYCN protein and AURKA 
induces the growth of MYCN-amplified NB cell lines suggested by in vitro 
analysis and the AURKA inhibitor alisertib (MLN8237) was able to inhibit the 
growth of NB xenografts (90). 
 
After three years from the first GWAS study, the cohort of genotyped NB 
patients increased and by comparing 1627 NB patients with 3254 controls, risk 
variants in CASC15 and BARD1 confirmed and additionally identified a new 
locus on 11p15.4 mapping to the LMO1 gene (91). The newly identified 
GWAS SNPs associated with the LMO1 gene can predict clinical outcome of 
NB patients and higher LMO1 expression contributes to the growth of NB cells 
(91). Increased LMO1 synergizes with MYCN In a zebrafish model of NB and 
promotes tumorigenesis (92). With the advancement of the GWAS studies, the 
susceptibility SNPs have been identified in other genes like DUSP12, 
HSD17B12, DDX4, IL31RA by comparing 574 low-risk NB cases with 1722 
control cases (93). 
 
Diskin et al. conducted a GWAS in 2012,  comparing a discovery cohort of 
2101 patients to 4202 European controls and besides confirming the previous 
findings, identified new risk variants in HACE1 and LIN28B that were 
associated with the development of NB (79). Furthermore, predisposition 
SNPs in HACE1 and LIN28B were confirmed in an African American cohort 
for the first time (79). HACE1 has been noted as a tumor suppressor in many 
cancers including NB (94) and LIN28B generally remains overexpressed in 
high-risk NB and elevates MYCN expression and stabilization by both 
inhibiting the miRNA let-7, and increasing RAN and AURKA expression (80). 
Whole exome sequencing and whole genome sequencing of blood leukocyte 
from 240 matched tumor and normal pairs also revealed germline pathogenic 
variants in ALK, CHEK2, PINK1, TP53 and BARD1 genes (95). Taken 
together GWAS studies can contribute to the clinically approachable biology 
in NB. 
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Figure 1.  Timeline of identified genetic variation in NB. GWAS, genome-wide 
association studies. Modified from Barr EK et al; Children; 2018:5(9)119. 
 
1.1.4 Neuroblastoma – a disease of differentiation 
NB arises from the neural crest (NC) cells, a transient population of embryonic 
cells in the developing sympathetic nervous system (3). The NC cells are 
generated at the dorsal edge of the neural tube (NT) of the vertebrate embryo 
under the guidance of some NC specific gene regulation. Further NC cells 
(NCCs) undergo an epithelial-to-mesenchymal transition (EMT) and migrate 
ventrally close to the neural tube and begin to differentiate to a plethora of cell-
types and tissues in response to local signaling modifications (96) . Some of 
the NC cells differentiate into neurons of the sympathetic ganglion and 
sympathetic ganglia like adrenal chromaffin cells (the catecholamine-secreting 
cells of the adrenal medulla) as mentioned in Figure 2 (97). Other adjacent 
neural crest-derived cells differentiate into Schwann cells (associated with 
neural axons and line the ventral roots of the spinal cord, chromaffin cells of 
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the adrenal medulla and melanocytes), and satellite cells (associated with 
neural cell bodies) (98). NB s and NB cell lines possess immature sympathetic 
neurons (sometimes called N-type cells) and Schwann cells (S-type cells) like 
cells. Patients with a higher proportion of Schwann cells in a tumor have a rare 
MYCN amplification and better outcome (99). On the other hand, MYCN 
amplification is present in immature neuronal NB cells in patient tumors and 
leads to malignancy as MYCN functions to maintain the pluripotent, 
proliferative state and to prevent differentiation of neuronal crest (43) (Figure 
2). 
NCCs can form multiple tissues or organs of an adult organism. NCCs consists 
of two major populations of cells– cranial NCCs and trunk NCCs (100). Trunk 
NCCs are originated from the caudal region of an embryo and migrate with the 
help of different pathways (100).  The differentiation potential of trunk NCCs 
is not only dependent on their initial genetic multipotency but also on the 
surrounding microenvironments, they face during migration (101, 102). 
Retinoic acid (RA) treatment induces differentiation of immature neuron-like 
cells into more mature neurons in vitro (103) but the possibility to differentiate 
into Schwann cells has not yet been studied therapeutically. Overall NB can be 
perceived because of the failure of neural crest cell differentiation, so 
understanding the mechanisms by which the key factors and pathways that 
regulate normal neural crest differentiation can help in identifying novel 
therapeutic targets and prevention as described by Tomolonis et al. (104). I 
have summarized some of the key pathways related to NC development and 
differentiation below.   
 
Regulation of NC development and differentiation through 
signaling pathways of bone morphogenic protein (BMP), 
Wingless/Int (WNT), Fibroblast growth factor (FGF), and 
Notch/Delta  
 
Neural crest Induction begins with neural tube development during 
gastrulation. The primary neural tube consists of non-neural ectoderm and 
neural plate (NP) tissues with the junction called the neural plate border (NPB). 
Modulation of the genes within this NPB region leads to NC induction (105). 
The major interconnected signaling pathways related to this process are bone 
morphogenic protein (BMP), Wingless/Int (WNT), Fibroblast growth factor 
(FGF), and Notch/Delta signaling. These signaling molecules trigger the 
transcription factors that allow for NC specification. 
BMP is a protein derived from the transforming growth factor-beta (TGFβ) 
family that is secreted by neighboring non-neural ectoderm of the primitive 
neural tube. The Smad family of transcription factors are activated by BMP 
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signaling and that leads to growth and differentiation-related gene 
transcriptional activation (106). Combination therapy using BMP-6 and 
retinoic acid derivatives led to synergistic differentiation of IMR32 NB cell 
lines into dopaminergic neurons as noticed by elevated expression of tyrosine 
hydroxylase, neuronal maturation in morphology, and inability to resume cell 
division (107). Furthermore, in mouse NB cell line neuro2a, the addition of 
BMP leads to decrease in inhibitors of differentiation and increasing neuronal- 
specific factors which leads to differentiation (108) (Figure 2). 
Wnt is another key-ligand that involves in NC induction by controlling β-
catenin signaling. Wnt secreted by neighboring non-neural ectoderm, binds to 
Frizzled receptors expressed on the cells of the NPB, and leads to the induction 
of β-catenin genes. Canonical Wnt signaling is both sufficient and necessary 
for NC induction (Figure 2). In NB, the role of the Wnt pathway in 
tumorigenesis is controversial. The decreased Wnt-5 expression could be 
reversed by retinoic acid differentiation therapy and this has been shown using 
an IGR-N-91 xenograft model and cell lines derived from the primary tumors 
(109). On the contrary, it has been shown that activation of canonical Wnt 
signaling through β-catenin in NB cell line SK-N-SH led to in 
vitro doxorubicin resistance (110). These two studies suggests in one way Wnt 
signaling promotes differentiation while others propose high Wnt activity leads 
to drug resistance as well.  
Fibroblast growth factor (FGF) is another important molecule that binds and 
signals through receptor tyrosine kinases, which are also known as fibroblast 
growth factor receptors (FGFRs). FGFR signaling activates many downstream 
pathways involved in proliferation and survival, including Ras/ERK and 
Akt/mTOR  (111). FGF signaling through FGFR4 activates STAT3 (signal 
transducer and activator of transcription 3) and leads to expression of NC 
border genes and NC specifiers, while the loss of FGFR4 prevents this 
induction, has been shown in a study (112). In NB cell lines, primary patient 
samples and xenograft mouse; STAT3 expression is associated with NB 
Cancer stem cells (CSCs)-like cell maintenance with increased tumorigenicity 
and chemoresistance (113). Moreover, use of STAT3 inhibitor Stattic led to 
decreased tumorigenicity, metastasis and chemoresistance in NB cell lines and 
xenograft tumor models (114).  
Notch pathway proteins are transmembrane signaling molecules and play a 
critical role in the maintenance of cells in a proliferative state with blocked 
differentiation. In NB cell line SH-SY5Y, Notch1 signaling inhibition led to 
neuronal differentiation via a JNK-CRT mediated pathway and 
correspondingly treatment of Notch inhibitors (γ-secretase inhibitors, GSIs) in 
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NB xenograft mice led to the suppression of tumor progression (115). 
Furthermore, the treatment with a combination of GSIs and retinoic acid 
derivatives of SH-SY5Y and IMR-32 human NB cell lines led to synergistic 
complete cell growth arrest, decreased cell mortality and promote neuronal 
differentiation (116). 
c-Myc and N-Myc dependent regulation  
c-Myc and N-Myc play an important role by directly modulating a gene 
network involved in pluripotency maintenance (117). c-Myc is activated by 
LIF/STAT3 signaling and maintains pluripotency (118). Myc is well 
implicated for maintenance of pluripotent like signature as it is one of the four 
Yamanaka transcription factors that can reprogram terminally differentiated 
cells into pluripotent stem cells and it acts via epigenetic modulation in early 
reprogramming process (119, 120). MYCN amplification, the strongest 
indicator of the high-risk status of NB and poor survival, leads to N-Myc 
protein upregulation in 50 % of high-risk NB tumors (43). MYCN amplified 
tumors basically consist of undifferentiated or poorly differentiated 
neuroblasts, regulated by N-Myc and other downstream signaling pathways 
(32). Chromatin Immuno Precipitation assay (ChIP-assay) after conditional 
expression of N-Myc in human NB cell line Tet21N, reveals that N-Myc can 
regulate some critical embryonic stem cell factors associated genes like 
LIN28B, LIF, KLF2 (41). 
SOX9 regulation of NC survival 
NC specifier genes have a late onset and they can trigger NC cells to initiate 
an EMT by assimilating the migratory phenotype. The key regulatory 
transcription factors involved in this transitional program are Sox9, Sox10, 
Twist1, FoxD3 and Snail2 (96, 121). Sox9 regulates the initiation of the EMT 
program by Ap2 signaling and promotes NC survival by cell cycle arrest and 
apoptotic inhibition via Snail2 regulation (96, 122).  The lncRNAs 
CASC15 and NBAT1 have been shown to promote differentiation in NB cells 
by regulating SOX9 expression via interacting with a deubiquitinase USP36 
(57). 
 
 
 
Understanding the role of long non-coding RNAs in neuroblastoma development and 
progression. 
12 
 
 
Figure 2. NB is a disease of differentiation. Neural crest derived cells undergo 
epithelial-to-mesenchymal transition (EMT) and are then subjected to migration 
and differentiation to wide range of cell types to form different anatomical 
structures. A complex network of signaling and transcriptional changes regulate 
this process. Deregulation of any of these events can trigger the changes in the 
properties of the migrating neural crest cells that leads to NB tumor formation. 
Adapted from Johnsen JI et al; Front Mol Neuroscience; 2019; 12: 9. 
 
PHOX2B regulation of NB tumorigenesis 
NB typically arises from sympathoadrenal (SA) progenitor cells which give 
rise to the sympathetic nervous system in the adrenal medulla (chromaffin 
cells) and paraspinal ganglia (97, 123). NC cells migrate from their origin after 
going through the EMT and destined to become SA precursors cells. SA 
precursors cells ventrally migrate from the neural tube and aggregate at the 
dorsal aorta and form the primitive sympathetic ganglia (124). The well-known 
transcription factor PHOX2B (paired-like homeobox 2b) is expressed almost 
in all noradrenergic neurons and plays a critical role in the neurogenesis in the 
autonomic nervous system. Loss of PHOX2B caused reduced expression of 
markers of autonomic neural crest development and lineage except for MASH-
1, in SA progenitors at the dorsal aorta and primitive adrenal gland (72, 125). 
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In NB patients PHOX2B expression is very common and it is used as a 
prognostic marker in patients after chemotherapy treatment to detect minimal 
residual disease (126). PHOX2B was identified as a key mediator of NB 
pathogenesis using a TH-MYCN mouse model, which correlates with MYCN 
expression and higher PHOX2B induces the proliferation of undifferentiated 
neuronal progenitor cells (127). Retinoic acid (RA)-induced neuronal 
differentiation can downregulate PHOX2B expression followed by 
suppression of the self-renewal capacity of NB cells and inhibition of 
tumorigenicity, and this once again confirmed PHOX2B has a key regulatory 
role in NB cell differentiation and stemness maintenance (75) (Figure 2). 
1.1.5 Status of p53 in Neuroblastoma 
Most stage 4 NB patients over 1 year of age remain chemo- and radiotherapy 
sensitive initially, but they gradually acquire resistance in relapsed tumors 
except a few who become long term survivors (128). p53 is a well-investigated 
tumor suppressor gene and it inhibits tumorigenicity by initiating cell cycle 
arrest, DNA damage repair and apoptosis in response to cellular stress signals 
like DNA damage or alkylating agents. Deregulation of the p53 tumor 
suppressor pathway has been a major cause for accumulating resistance to 
cytotoxic therapy in many tumor cells (129). Interestingly, in 60% of all human 
cancers approximately, p53 remains mutated but in NB tumors, p53 mutations 
are very rare, only 1.9% of NBs (4 out 208 tested NB tumors) have been 
reported by whole genome sequencing (130, 131) possessing p53 mutation. In 
the absence of mutation, p53 functional inactivation can happen in different 
ways and affects the p53 downstream function. The functional inactivation of 
p53 is believed to occur due to other mechanisms, for example, viral 
inactivation, MDM2 amplification and deletion of the INK4a-ARF gene 
encoding p14ARF (132) or altered subcellular localization of p53. Preferential 
cytoplasmic accumulation of wild type p53 with loss of nuclear p53 has been 
identified in several studies, which leads to functional inactivation of p53 in 
undifferentiated high-risk NB tumors (133-135). Cytoplasmic localization of 
wild type p53 in 96% (30 among 31 cases) of tested undifferentiated NB 
tumors was observed with 4.5 to 8 fold increase of p53 protein level over 
normal and no MDM2 gene amplification. Whereas 14 differentiated tumors 
showed no abnormalities of p53, suggesting p53 cytoplasmic localization is 
the cause for functional inactivation of p53 in undifferentiated NB tumors 
(134). Subsequently, the aberrant cytoplasmic localization of wild type p53 in 
NB tumors associated with elevated Thr-55 phosphorylation of P53, which 
induces p53 and CRM1 (nuclear export factor) interaction and that leads to 
cytoplasmic export of p53. Inhibition of Thr-55 phosphorylation can restore 
the p53 nuclear localization in NB cells (136). However, the p53 subcellular 
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localization in NB remains controversial. The above examples of 
investigations support the aberrant cytoplasmic localization of p53 as a cause 
of p53 functional inactivation in high-risk NB. But on the contrary, others 
support p53 accumulated in nuclear compartment and remain functional 
regardless of differentiation status of NB tumors (137) or despite cytoplasmic 
localization, p53 signal transduction pathway remains intact (138). Hence 
understanding the different mechanisms related to p53 irregular function in 
NB, may contribute to develop alternative therapeutic strategy. 
1.1.6 Neuroblastoma disease models 
NB causes 15% of pediatric death, this necessitates the advancement of novel 
therapeutic approaches for battling against NB (139). The development of 
advanced therapeutic strategies in NB is dependent on the in vitro and in vivo 
disease model system to pilot the experimental-therapies. Cell culture and 
xenograft  represent preclinical models for developing new therapeutic 
approaches to treat NB tumors. Development of the new disease models can 
answer many unaddressed questions, like how a segmental chromosomal 
alteration leads to NB tumor formation or how gene epistasis contribute to 
developing disease phenotype, or the recurrent mutations in the genes in a 
particular chromosomal locus have a concerted effect on NB cancer 
development. The ability to understand how acquired mutation, chromosomal 
copy number changes or loss/gain of gene segments contribute to NB 
development demands NB disease models. Disease models can be also used to 
evaluate and identify novel drugs that can target responsible pathways which 
contribute to NB. 
In vitro disease model 
Cultured cancer cells are widely used as an important in vitro model for 
identifying the disease biomarkers and testing anti-cancer compounds pre-
clinically. One of the most used NB cell lines is SH-SY5Y (non-MYCN 
amplified), which is sub-cloned from its original parental cell line SK-N-SH 
(140). The importance of this cell line is it possesses many characteristics like 
dopaminergic neurons as it express tyrosine hydroxylase (TH) and dopamine- 
β-hydroxylase as well as the dopamine transporter, on the other hand, SH-
SY5Y can be differentiated into fully mature neurons with the help of various 
differentiation triggering agents (for example RA). A number of other NB 
model cell lines have been used in research. They are able to proliferate in vitro 
and remain undifferentiated and also capable of differentiation into neuronal 
cells depending on their risk-trait. For example, IMR32 (141), Kelly (142), 
NB69 (143), SK-N-DZ, SK-N-BE2, SKNAS (144) and SHEP are used as in 
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vitro cell models of NB. Neuro2a cells are a fast-growing mouse NB cell line, 
used as an in vitro NB model system. 
In vivo disease model 
Preclinical in vivo models of NB are essential for developing new therapeutic 
strategies and testing new chemotherapeutic drug combinations for clinical 
trials. The TH-MYCN mouse model is the most widely used transgenic 
model for preclinical testing of NB. This NB -prone mouse model resembles 
many of the characteristics of human MYCN amplified NB, established by 
driving MYCN expression using the rat Th promoter containing a strong 
enhancer from the rabbit β-globin gene (47). TH-MYCN mouse model has 
been used to understand role of p53 in neuroblastoma development and  
chemotherapeutic resistance (145). Another transgenic mouse model in NB is 
LSL-MYCN; Dbh-iCre with Cre-conditional induction of MYCN in dopamine 
β-hydroxylase-expressing cells. Approximately >75% of these mice also can 
develop neuroblastic tumors, regardless of strain background and are used for 
developing novel targeted therapy (146).  
Another in vivo NB model is the chick chorioallantoic membrane (CAM) 
xenograft model which has been used for many years to support the NB tumor 
growth and for testing new therapies in pre-clinical trials. The differentiation 
status of NB tumors, which is formed on the chick CAM, can be analyzed by 
observing the changes in gene expression, proliferation and cell morphology 
(147). A microenvironment-driven pro-metastatic switch for NB has been 
identified by making several stable NB cells expressing fluorescent markers 
and grafted them into the sympatho-adrenal crest level of HH14 chick embryos 
and analyzed grafted embryo at HH25 in transverse slices and 3D imaging and 
tracking the movement of NB cells (102). Promoting NB differentiation with 
the all-trans-Retinoic acid (ATRA) is well described and this effect was 
recapitulated in the chick embryo NB model (148, 149), therefore this model 
provides a rapid, cost-effective in vivo model in NB for selecting promising 
drugs for preclinical analysis. 
The zebrafish model system also emerges as an invaluable model system in 
NB. Presently this exciting in vivo model system is also in use for high-
throughput drug screening as it provides a visual assessment of both drug 
efficacy and drug toxicity (150). The first zebrafish model of NB was 
generated by Zhu et al. by driving the expression of MYCN using dopamine-
β-hydroxylase (dβh) driven promoter and in this model overexpression of 
mutant ALK act in synergistic manner to induce tumor formation (64). This 
zebrafish model system has become an essential tool for the study of ALK and 
MYCN-driven NB, which is complementary to in vitro cell culture-based drug 
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screens (68, 151). As only 20-30% of NBs harbor MYCN amplification, the 
zebrafish model of other important drivers of high-risk NB has to be 
developed. 
Drosophila melanogaster also remains another important genetic model for 
NB to identify promising drug compound and to understand mode of action of 
NB disease causing gene like ALK. In a study, transgenic Drosophila were 
generated with ectopic expressions of different human ALK mutants, 
expressed in the Drosophila eye to define the role of 3 classes of ALK 
mutations in NB and their ligand dependency was characterized (152). 
Drosophila ALK model has been also successfully used to check the efficacy 
of ALK inhibitor Briganitib (153).  
1.1.7 Neuroblastoma treatment strategies 
A multidisciplinary team of doctors treat a NB patient and used to make 
decisions of treatment strategies and recommendations depending on several 
factors, for example:-  
 The size and location of the tumor 
 Malignancy of the tumor, whether the tumor is spread 
 The risk-group classification of the tumor 
 Possible side effects 
 Preferences of the family 
 Overall child health and other conditions 
Patients under observation  
Small infant group (0-6 month) with localized NB, do not need any treatment, 
not even surgery. Generally, these children with small tumors remain under 
close observation, physical examination and laboratory tests. The majority of 
these tumors regress by their own without further treatment except in the 
instance of tumor growth, when surgery with or without chemotherapy is 
recommended. In most of the cases these group of patients survive. (154).  
Surgery 
Surgery is a process of a tumor and some surrounding healthy tissue removal. 
The surgical oncologists remove the entire tumor when the cancer has not 
spread but mostly NB is diagnosed after the cancer has spread. So as much of 
the tumor as possible is removed during surgery, followed by chemotherapy 
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and radiation therapy to destroy the remaining cancer cells. Also a biopsy is 
usually done to detect the tumor type (154). 
Chemotherapy 
Chemotherapy is the particular drug or combination of drugs to destroy cancer 
cells, by reducing the ability of cell growth. Most NB patients will need to have 
chemotherapy either for primary treatment or for shrinking of the tumor before 
surgery or destroying cancer cells after surgery. Chemotherapy is chosen based 
on the NB risk group. Intermediate-risk group children often receive 
Carboplatin, Cyclophosphamide, Doxorubicin or Etoposide (155, 156). On the 
other hand high-risk group children often receive Busulfan, Cisplatin, 
Cyclophosphamide, Cytokines, Etoposide, Topotecan, Vincristine or 
Melphalan (155, 156). There are dose-dependent and variable side effects from 
patient to patient. However, in recent years the cure rate has not significantly 
improved (156). 
Radiation therapy 
Sometimes radiation therapy, which is high-energy x-rays or other particles, is 
used in NB patients to destroy cancer cells. External-beam radiation therapy 
from a machine outside the body is the most common type of radiation 
treatment. There are severe side effects of radiation therapy. Sometimes 
radiation therapy can hinder the normal growth and development of a child’s 
brain and the testicles in boys and ovaries in girls, so other treatment strategies 
are opted for first (157). 
Retinoic Acid Therapy 
NB is a disease for poorly differentiating tumor cells, so induction of the 
differentiation should reduce the growth and proliferation in these cancer cells. 
It is evident from several scientific reports that 13-cis retinoic acid induces 
differentiation and reduces cancer cell proliferation in NB cells (35, 86). 
Generally, high-risk patients are also treated with RA and children with 
treatment reported to have improved event-free survival and reduced toxicity 
(158, 159). 
Immunotherapy 
Immunotherapy is designed for boosting the body’s natural defense system to 
fight against cancer. The compounds used in immunotherapy made either by 
the body or in the laboratory, to target the abnormal antigen formed during 
cancer development and restores the immune system function. NB cells 
express a high level of sialic acid and gangliosides such as a compound called 
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disialoganglioside (GD2) on their cell surface (160). This agent is required for 
cell adhesion, migration and metastasis (161). Immunotherapy using anti-
monoclonal antibody directed against GD2 has been used for treating NB 
patients. The clinical trial testing has been conducted with anti-GD2 
monoclonal antibody therapy (dinutuximab) combined with cytokines and 
retinoid therapy versus only RA therapy in high-risk NB patients. Dinutuximab 
(Unituxin) was approved as a first-line therapy for high-risk patients by the 
U.S. Food and Drug Administration (FDA) in 2015 (162). 
Targeted delivery of radionuclides 
A radionuclide named I-metaiodobenzylguanidine (131I-MIBG) also has been 
implicated as a therapy of NB, which helps to increase the cure rate of stage 3 
NB patients and improve the response (measured by considering the tumor 
volume, numbers of metastatic lesions and level of urine catecholamines) of 
stage 4 NB patients, but long term toxicity is a risk factor for this treatment 
(163). 
Bone marrow or stem cell transplantation 
Diseased bone marrow can be replaced by highly specialized cells called 
hematopoietic stem cells, which are blood-forming cells and found both in 
bloodstream and in the bone marrow. This transplantation can destroy the 
cancer cells in the bone marrow, blood and other body parts and allow them to 
create healthy bone marrow with the blood stem cell replacement.  This 
transplantation process is called bone marrow transplantation, but recently it 
has been more often called stem cell transplantation, though not actual bone 
marrow tissue is transplanted, but rather blood stem cells. Depending on the 
source of the replacement of blood stem cells, there are two different kinds of 
transplantation, allogeneic (ALLO) and autologous (AUTO). In high-risk NB, 
AUTO transplants are often used. Different combinations of high dose 
chemotherapy are usually opted prior to the transplantation (154).  
Targeting MYCN and ALK 
MYCN status in NB patients remains a valid and most important prognostic 
marker for NB diagnosis (1, 3), which indicates targeting MYCN expression 
in high-risk NB patients could be beneficial for treatment. As drugs cannot 
directly bind to the DNA binding domain of MYCN due to the lack of the 
appropriate binding motifs (164), targeting MYCN indirectly to regulate its 
activity has recently become a widely accepted approach. For example, Aurora 
kinase A/B inhibitors, inhibitors of MYCN/MAX interaction, BET 
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bromodomain family members inhibitors P13K/AKT/m TOR inhibitor, ALK 
inhibitors are used as indirect targeting of MYCN (159, 165, 166). In recent 
studies it has been shown that ALK can transcriptionally regulate MYCN via 
AKT/ERK5 pathway, indicates that targeting ALK and its downstream targets 
in ALK- positive NB cell lines might be a potential therapeutic target by 
controlling MYCN expression in NB patients (165, 166). There are several 
ALK inhibitors are in use and have been developed and explored in clinical 
trials in recent years, for example Crizotinib, Ceritinib, Brigatinib, 
Loratinib(167, 168). 
Tyrosine kinase inhibitors 
 
It has been shown a small molecule inhibitor of Trk tyrosine kinase, CEP-701 
can inhibit the growth in NB in vivo and a phase I trial is ongoing clinically 
(169). There are few more tyrosine kinase inhibitors, which are in clinical trials 
as well for example epidermal growth factor receptor (3, 170). 
 
1.2 Non-coding RNA 
 
The emerging evidences from high-throughput genomic and transcriptomic 
studies suggest that the portion of the genome which has the protein-coding 
potential is more or less constant across the evolutionary ladder, while the non-
coding portion of the genome which is transcribed into RNA but does not code 
for any protein has expanded significantly, indicating that the complexity of 
developmental processes in higher organisms is probably due to expansion of 
regulatory potential of the non-coding portion of the genome. Only a minor 
portion (2%) of the pervasively transcribed eukaryotic genome accounts for 
the protein-coding RNA, the major portion (98%) of the transcribed genome is 
non-protein coding which includes both intergenic and intronic sequences, as 
shown by the high-throughput RNA-sequencing studies in recent years (171-
173). Simultaneously the Encyclopedia of DNA Element (ENCODE) analysis 
reveals that 80 % of the genome has a “biochemical function”, which indicates 
that the non-coding portion of the genome is not junk as was previously 
thought before (174). 
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1.2.1 Non-coding genome and organismal 
complexity 
The evolution of organismal complexity in higher eukaryotes has been a long-
raised and fascinating question. Recent high-throughput studies helped us to 
visualize the developing genomic complexity to the multi-cellular higher 
eukaryotes based on the number of protein-coding genes. Burkholderia 
xenovorans, a free-living bacterium contains 8602 protein- coding genes (175), 
while the number of estimated protein-coding genes in humans is in the range 
of 20,000-25,000 which almost similar number protein-coding genes as present 
in the nematode (176), Caenorhabditis elegans with around 19,735 protein-
coding genes (177). These observations bring us to the ‘G-value’ paradox, 
which depicts that the number of the protein coding genes has not changed 
much from the worm with only 1000 cells to the human with diverse cell types 
(175). Thus, there are some different multilayered mechanisms present in the 
higher organisms to efficiently control the complex system. The Organismal 
complexity is partly explainable by the presence of alternative splicing, RNA 
editing, trans splicing, alternative promoter uses but the enormous genetic 
changes that can contribute to the cellular complexity of higher eukaryotes, are 
largely unexplored. On the other hand as the non-coding portion of the genome 
has increased significantly in the higher complex organism (178), this part of 
the genome has gained attention recently and might be a contributor to genomic 
complexity as well. Previously most of the non-protein coding portions of the 
genome were thought to be junk or selfish DNA, with the exception of some 
regulatory regions like insulators and enhancers (179). But with the 
advancement of high-throughput studies it has been clear that major part of the 
non-protein coding genome transcribes RNAs that called non-coding RNA 
(ncRNA) (171, 172), which lack coding capacity. Along with that in the 
mammalian genome, a large number of protein-coding genes have the 
antisense counterparts, indicated by FANTOM3 consortium and also intronic 
regions of protein coding genes are transcribed as well to generate the intronic 
transcripts (180). All these contributes to a complex transcriptional output 
(181). 
 
After understanding the intriguing complexity of the human transcriptome, the 
next and obvious question is how does this massive non-coding transcriptional 
output beside the protein-coding genes contribute to the higher organismal 
complexity? To elucidate this question, there are many investigations reported 
over the years that suggest the non-coding portion of the genome has a diverse 
and significant role in bringing cellular complexity. Interestingly, a subset of 
ncRNAs has been implicated in epigenetically regulated biological phenomena 
like X chromosome inactivation in female mammals (182, 183), genomic 
imprinting (184-187), homeobox gene regulation (188) and maintenance of 
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pluripotency (189-191). On the other hand many ncRNAs, such as PCAT-1, 
MALAT-1, HOTAIR and ANRIL have been implicated in tumor initiation and 
progression in several cancers (192-196). Therefore, there is a clear indication 
that evaluating and characterizing that non-coding region of the genome could 
solve the puzzle about organismal complexity partially by explaining complex 
phenotypes in higher organisms. 
 
1.2.2 Classes of non-coding RNAs (ncRNAs) 
Distinct classes of the ncRNAs have been identified using high throughput 
approaches in divergent tissue types and distinct developmental stages in the 
eukaryotic genome. The ncRNAs are mainly comprised of major two 
categories, ncRNAs of the first category are highly abundant and housekeeping 
in nature such as transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs) and 
the second category ncRNAs are regulatory in nature. Regulatory ncRNAs can 
be classified again in two different subtypes according to their size – small 
non-coding RNAs and long non-coding RNAs. Small non-coding RNAs are 
microRNAs (miRNAs), small nuclear RNAs (snRNAs), short-interfering 
RNAs (siRNAs), small nucleolar RNAs (snoRNAs), piwi-interacting RNAs 
(piRNAs) and extracellular RNAs (exRNAs), which are highly conserved and 
involved in transcriptional and post-transcriptional silencing of genes. 
Whereas long non-coding RNAs (lncRNAs) which are more than 200nt in 
length, moderately conserved and can be sub-divided into circular RNAs 
(circRNAs) and linear lncRNAs such as antisence, intergenic, intronic, 
competing endogenous RNAs (ceRNAs) etc. LncRNAs regulate gene 
expression through a plethora of mechanisms and contribute to crucial 
biological functions, among which a small portion has been identified and 
understood to date (197, 198) for example genomic imprinting, cellular 
differentiation, pluripotency maintenance, RNA maturation and transport, 
sponging miRNA and gene regulation, X-inactivation and signal transduction 
(173, 199-203). The accumulating evidence indicates that lncRNA has an 
extensive role in the eukaryotic gene regulatory network and understanding 
and uncovering their significant functional roles in greater detail can enable us 
to better understand the genomic complexity in the higher organism (204). In 
the current thesis, our interest is to identify and characterize lncRNAs in NB 
tumor development and progression. 
 
 
 
Understanding the role of long non-coding RNAs in neuroblastoma development and 
progression. 
22 
 
1.2.3 Long non-coding RNAs (lncRNAs) 
The current thesis is focused on long non-coding RNAs (lncRNAs) subtype of 
ncRNAs. lncRNAs are more than 200 nucleotides in length and lack protein-
coding potential. lncRNAs are transcribed by RNA polymerase II as other 
protein-coding genes, capped, polyadenylated mostly and spliced frequently 
(205-207). lncRNAs are localized in both nuclear and cytoplasmic 
compartments and found in almost all tissue types but in the brain and central 
nervous system, the abundant expression of lncRNAs has been noticed (208).  
According to the comparative studies lncRNAs have lesser but longer exons 
generally compared to exons of protein-coding genes (209). LncRNAs usually 
overlap with more repetitive RNAs than mRNAs (210) and they are less 
efficiently spliced and possess less transcription factors and histone marks 
binding to the promoter region in comparison with mRNA (211).  
 
Identification of long non-coding RNAs 
By analyzing the full-length cDNA libraries in the mouse, the first long non-
coding RNAs were identified (212). With the advancement of sensitivity of 
genome tiling arrays, many more lncRNAs were annotated, revealing that the 
number of non-coding sequences is significantly larger than protein-coding 
sequences in human genome. Many other approaches gave sensitivity to 
lncRNAs detection such as tilling microarrays combining with genome-wide 
chromatin maps using H3K4me3-H3K36me3 active histone marks detected 
1600 long intergenic non-coding RNAs (lincRNAs) (205, 206).  Cap analysis 
of gene expression (CAGE-seq) (207) provided high-resolution mapping of 
precise transcription start sites where as poly(A)-position profiling by 
sequencing (3P-seq) helped to map the 3´end of the transcript precisely (213). 
Combining both the CAGE-seq & 3P-seq have further contributed to the 
annotations of novel and stable lncRNA transcripts. According to the latest 
version of GENCODE analysis, human genome comprised of 58,288 genes in 
total and of which 19,836 gene transcripts code for protein and the rest amount 
of genes are non-coding transcripts among them 15,778 are lncRNA genes 
only, indicating that the number of protein-coding genes are almost similar to 
the number of lncRNAs in human genome (214, 215). 
 
Evolutionary perspective and conservation of lncRNA 
lncRNAs are not that conserved and evolved more rapidly than protein-
coding genes. Whole-genome alignment of human and mouse lncRNAs 
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revealed that the exonic region and promoter regions of lncRNAs are 
evolved much more slowly or are more conserved than intronic regions of 
lncRNAs and intergenic regions of the genome (206, 209, 216). Strikingly, 
despite any sequence homology in genomic alignment-based estimation, 
many lncRNAs possess a conserved genomic organization including exon-
intron structure (210). These phenomena suggest that these lncRNAs 
might have conserved sequence-based function but current available tools 
are not sufficient to identify this sequence conservation. For example, 
Malat1, which is a known, frequently, expressed, nuclear-localized, 
single-exon transcript and thought to be mammalian specific according to 
its genomic alignment conservation. But recently orthologues of Malat1 
have been identified in mammals, fish and frogs containing the same 
length, exon-intron structure and expression pattern. Though except in the 
3’ terminal part, which has a 70 base homology region there are no 
significant sequence conservation of mammalian Malat1 with its fish 
orthologue (210). Overall, it suggests that it is inaccurate to predict the 
functionality of lncRNAs considering their sequence conservation.   
lncRNA subtypes 
lncRNAs can be categorized and divided into several classes depending on 
their position in the genome, distance from protein-coding genes, 
functional diversity or different approach of processing such transcripts. 
Some categories of lncRNAs are described in Figure 3. Intronic sense and 
antisense lncRNAs are transcribed from introns of a protein-coding gene 
with the same and opposite directions to the protein-coding gene 
transcription respectively (217). Long intergenic RNAs (lincRNAs) 
transcribed from the intergenic region of the genome or a separate 
transcriptional unit from protein-coding gene (217). Whereas enhancer 
lncRNAs transcribe from an enhancer region having a capability to 
enhance the protein-coding gene transcription on the same locus (218). 
Divergent lncRNAs are originated from bidirectional promoter where 
lncRNAs share the promoter of protein-coding genes and might have a cis-
regulatory function on the protein-coding genes. On the other hand, 
circular lncRNA produced from long primary transcripts only but in an 
unusual RNA processing pathway that gives the RNA circular structure 
(218).  
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Figure 3. The subtypes of long non-coding RNAs (lncRNAs): A) Complimentary 
intronic and intronic antisense lncRNAs. B) Long intergenic RNA (lincRNA) C) 
Enhancer RNA (eRNA) D) bidirectional divergent lncRNA D) Circular RNA 
(circRNA) generated for back splicing of exons. 
 
1.2.4 lncRNA ‘mode of action’  
lncRNAs possess many important roles in biological development and 
disease. They are involved in various mechanisms like epigenetic 
modification of gene expression, chromatin remodeling and also gene-
regulation in transcriptional and post-transcriptional levels. The broad 
landscape of the different mode of actions of lncRNAs can be narrowed 
down in 4 major categories of actions as described by several studies (201, 
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219) and these are lncRNA mediated decoy, scaffold, guide and acting as 
enhancer RNAs (Figure 4). 
Decoys 
This mechanism of action is mainly titrating away several DNA binding 
proteins like transcription factors and prevents their access to the target 
regions of DNA. For example, Gas5 lncRNA binds to the DNA-binding 
domain of glucocorticoid receptor and prevents glucocorticoid receptor 
binding to DNA. During growth factor starvation, the elevated level of 
Gas5 lncRNA helps in a decoy to release the receptors from DNA and 
prevent the transcription of the metabolic genes (220). Another example 
the decoy mechanism of lncRNA is the lncRNA PANDA which decoys the 
transcription factor NF-YA and prevents its binding to the DNA and 
transactivation of several apoptotic related genes and finally block p53 
mediated apoptosis (221).  
The decoy function of lncRNA can be explainable in another aspect; 
lncRNA can sequester miRNAs as well and prevent miRNA mediated 
silencing of mRNA expression via acting as a sponge or competing for 
endogenous RNAs (ceRNAs). For example, lncRNA SNHG7 directly 
interacting and sponging miR-216b prevents miRNA mediated gene 
degradation of GALNT1 and EMT markers (E-cadherin and Vimentin) 
which leads to higher proliferation, migration and invasion in colorectal 
cancer (222). Another example of ceRNA is lnc-MD1, which sponges mir-
133 and regulate mir-133 dependent muscle specific transcription factor 
MEF2C (223). 
Scaffold 
Another important mode of lncRNA function is it can act as scaffold, 
where RNA acts as adaptor and binds to two or more protein partners and 
form an RNA-protein complex and regulate biological functions. For 
example, TERRA or the telomerase RNA TERC modulates telomerase 
function by scaffolding or assembling the telomerase complex (224). 
HOTAIR lncRNA, which regulates the gene expression by binding to both 
polycomb repressor complex 2 (PRC2) and LSD1-coREST complex 
(225). Kcnq1ot1 is another example of the scaffold, which promotes the 
transcriptionally silenced state by the two silencing histone marks 
H3K27me3 and H3K9me3 via interacting with the PRC2 and G9a both 
(185). This RNA-scaffold mechanism has been shown in many lncRNAs 
Understanding the role of long non-coding RNAs in neuroblastoma development and 
progression. 
26 
studies, gaining its functional importance in lncRNA mediated gene 
regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The ‘mode of action’ of the lncRNAs: Four major kinds of functions of lncRNAs 
- Decoy, Scaffold, Guide and Enhancer are represented in the figure. Concept taken from 
John L Rinn et al; Annu Rev Biochem; 2012; 81:145-66 
Guide 
This mechanism is required for appropriate localization of specific protein 
complexes. HOTAIR lncRNA is an example of guide lncRNA. HOTAIR 
lncRNA derived from HOXC locus and in trans it guides PRC2 complex 
to HOXD locus. HOTAIR lncRNA regulate gene expressions in trans in 
breast cancer cells leading to invasiveness and metastasis (226). LincRNA-
p21 gets induced by p53 during DNA damage and then binds to hnRNP-K 
and guides this protein to bind to the specific promoter for the regulation 
of p53 mediated gene apoptosis (227).   
ce RNA 
AAAA 
Different Protiens or  
transcription factors 
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Enhancer RNAs  
Enhancer RNAs are the lncRNA transcripts, which originate from 
enhancer region and enhancer transcription is mostly bidirectional.  Some 
of the enhancer RNAs may lack a poly A-tail and have very low copy 
number (228). These enhancer RNAs can modulate the expression of 
neighboring genes by associating with the promoter-enhancer complex. 
For example, HOTTIP, an enhancer like lncRNA interacts with WDR5 
protein, maintains the H3K4me3 active histone mark, and leads to gene 
activation. After encoding from 5’ region of HOXA gene cluster a 
chromosomal looping of HOXA gene brings enhancer like HOTTIP 
lncRNA to the proximity to the multiple HOXA genes (229). 
1.2.5 LncRNA and chromatin interaction 
Among the plethora of functions of lncRNA, I will be highlighting the 
chromatin interaction of lncRNAs in the current thesis. Before I describe 
the chromatin interacting lncRNAs, I will provide a small summary how 
chromatin marks control gene expression. Histones are the major 
component of chromatin, which wrapped around the DNA. The histone 
tails can have different modifications. Like tri-methylation at 4th lysine of 
Histone H3 tail (H3K4me3) over gene promoter or at tri-methylation of 
H3 at 36th position of lysine (H3K36me3) over gene body leads to 
transcriptional activation. Histone modifications can also dictate gene 
repression, for example tri-methylation of H3 tail at lysine 9 (H3K9me3) 
leads to gene silencing. Histone modification of chromatin is established 
by chromatin modifying enzymes and for specific chromatin modifications 
the chromatin modifiers also varies (230).  Chromatin interaction is a well-
known mechanism adopted by lncRNAs as they are able to interact with 
chromatin-modifying enzymes and target these specific epigenetic 
modifiers to target gene loci in cis or trans.  
Some of the cis-regulatory lncRNAs are Xist/RepA, Airn and Kcnq1ot1, 
they have been shown to be associated with repressive complex PRC2 to 
regulate gene expression in an allele specific manner. Imprinted lncRNAs- 
Airn and Kcnq1ot1 expressed from one parental allele and by interacting 
with chromatin modifiers and recruiting them over the repressed gene 
promoters leads to formation of silent chromatin (185, 231). RepA is 
transcribed from the repeat element present within the Xist gene and it 
promotes the formation of the transient heterochromatic structure by EZH2 
interaction over the Xist promoter of the future inactive X chromosome 
which is important for Xist induction and spreading of Xist lncRNA over 
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the inactive X-chromosome (232). The repressive chromatin complexes 
can be recruited by some specific protein binding domain or regions or 
motifs in lncRNA such as a GC rich double stem-loop structure (28nt) in 
RepA lncRNA interacts directly with EZH2 (232). These functional 
regions or structural motifs of lncRNA can act as a scaffold and recruit 
interacting protein partners and guide these complexes for efficient 
targeting of the repressive epigenetic machinery.  
One of the first described lncRNA mediated epigenetic regulation in trans 
can be exemplified by HOTAIR intergenic lncRNA transcribed from 
HOXC locus and it can mediate gene regulation of HOXD locus in trans 
via interacting and recruiting PRC2 protein complex like EZH2 and 
SUZ12 (188). HOTAIR lncRNA also has been shown to possess two RNA 
domains, one domain which at the 5’ end, interacts with PRC2 and another 
domain at the 3’ end interacts with LSD1, an H3K4me3 demethylase 
(225). In the first study of this thesis, we have shown that NBAT1 lncRNA 
suppresses its target genes related to cell proliferation and migration via 
interacting with EZH2 and establishing H3K27me3 inactive modification 
at the promoters of some of these genes in a trans-regulatory manner (86). 
1.2.6 LncRNA mediated protein stability 
Ubiquitination is a most important post-translational modification where 
ubiquitin is added to the target protein sequences and reduces protein 
stability via degradation. The highly conserved protein Ubiquitin is 
consists of 76 amino acid residues and universally found in all eukaryotic 
tissues (233). The process of ubiquitination can be divided into two groups 
depending on the numbers of ubiquitin molecules linked to protein; 
monoubiquitination or polyubiquitination. Polyubiquitin chains formed 
via conjugating the monomers with either several lysine residues or with 
N-terminal methionine residue and produce various ubiquitin signals 
(234). The C-terminal glycine of ubiquitin attaches to the Lysine residue 
of target proteins by an isopeptide bond as a post-transcriptional 
modification and marked as degradation signal for the target proteins (233, 
235, 236). There is a series of enzymatic events with the sequential 
function of ubiquitin-activating enzymes (E1), ubiquitin-conjugating 
enzymes (E2), and ubiquitin ligases (E3) which together build the 
degradation mechanism of the ubiquitin-proteasome system (UPS). A 
covalent bond transfer with ubiquitin occurs at each enzymatic step to 
finally the target protein (237, 238). Ubiquitination possesses many other 
important roles besides proteasomal degradation in several vital cellular 
mechanisms, such as DNA repair, cell cycle regulation and gene 
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expression. Interestingly there is a group of proteins called 
Deubiquitinating enzymes (DUBs), which play an antagonistic role by 
removing monoubiquitin or polyubiquitin chains from target proteins and 
reverse the fate of protein stability.  In human, there are almost 102 
putative DUB genes, which categorized mainly into two types cysteine 
proteases and metalloproteases. Metalloproteases are consisting of large 
number (58) of ubiquitin-specific proteases (USPs). This ubiquitination 
and deubiquitination mechanisms can fine-tune the stability of the proteins 
in the cellular system.  
Presently, there are many pieces of evidence to support the idea that 
lncRNA can mediate the ubiquitination process and modulate the 
ubiquitin-proteasome system with a role in human cancer. For example, 
HOTAIR lncRNA binds to E3 ubiquitin ligases Mex3b and Dzip3 and then 
binds to their target proteins Snurportin-1 and Ataxin-1 respectively, 
finally form a scaffold with all of them and target them to the proteasome 
machinery by enhancing target-substrate ubiquitination followed by 
degradation of target proteins tested in HeLa and human fibroblast cells 
(239). Another example of HOTAIR lncRNA driven ubiquitination has 
been shown in prostate cancer. HOTAIR can bind to the androgen receptor 
(AR) and stabilize it via blocking the binding of MDM2 (E3 ubiquitin 
ligase) to AR and prevent its ubiquitination followed by protein 
degradation (240). NDRG1-OT1 is another hypoxia-responsive lncRNA, 
which is responsible for inhibition of both NDRG1 mRNA expression and 
NDRG1 protein levels. NDRG1-OT1 destabilizes NDRG1 by ubiquitin-
mediated proteolysis, shown in the breast cancer cells (241). In our 2nd 
study of this thesis, we identified that low expression of 6p22 derived 
lncRNAs CASC15 and NBAT1 contributes to SOX9 upregulation by 
regulating cellular localization of USP36, a DUB (57). These above 
observations suggest that lncRNAs have an important role in the regulation 
of protein stability in two different ways either by modulating 
ubiquitination of protein via E3-ubiquitin ligases followed by proteasome 
degradation or by modulating de- ubiquitination of a protein by regulating 
function of DUBs to restore the stability of ubiquitinated proteins. 
1.2.7 LncRNA regulation in cancer 
With all the above discussions, it is quite clear that lncRNAs are the crucial 
fine tuners in the regulation and maintenance of the cellular state. Now in 
this section, I would like to discuss the direct implication of lncRNAs in a 
disease like cancer. The emerging evidence in last few years strengthened 
the concept that lncRNA function in both tumor suppression or in 
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tumorigenesis. The regulatory lncRNAs in different types of cancers are 
listed in table.1, with their functional role and interactive protein partners 
(Table.1). 
Tumor suppressor lncRNAs 
lncRNAs can fine-tune the p53 tumor suppressor pathway by actively 
participating in the pathway or they can act as tumor suppressors by 
themselves often in several types of cancers. p53 is an important tumor 
suppressor gene and its function is well studied in cancer research. p53 can 
activate numbers of genes related to cell cycle arrest and apoptosis and 
many lncRNAs are also involved in this p53 mediated gene regulatory 
pathways in cancers (242). 
Maternally expressed gene 3 (MEG3) lncRNA is reported to possess 
tumor suppression characteristic in different cancers, as it can stimulate 
p53 mediated transactivation by directly binding to the p53 DNA binding 
domain (243). MEG3 has an opposite correlation with tumor sizes and 
metastasis in cervical tumors (244) and similarly, MEG3 downregulation 
also leads to autophagy and increased cell proliferation in bladder cancer 
(245). In hepatocellular carcinoma cells MEG3 lncRNA inhibits cell 
growth via sponging miR-9-5p and upregulate SOX11 (246). Additionally 
in glioma, overexpression of MEG3 also cause reduced proliferation, 
migration and invasion by regulating the miR-96-5p/MTSS1 signaling 
pathway (247). Overall MEG3 lncRNA represents a tumor suppressor 
lncRNA in various cancers. 
Another well-studied p53-regulated lncRNA is lincRNA-p21, which is a 
co-activator of p21 expression as it controls p21 in cis. In diffuse large B 
cell lymphoma (DLBCL) cell lines, over activation of lincRNA-p21 causes 
decreased cell proliferation and cell cycle progression and higher 
expression of lincRNA-p21 leads to progression-free and overall survival 
in DLBCL patients as well (248). Consistently in colorectal cancer (CRC) 
lincRNA-p21 enhances the sensitivity to radiation therapy by promoting 
apoptosis and decreased level of lincRNA-p21 correlated with CRC disease 
progression (249, 250). 
Another tumor suppressor lncRNA has been investigated in Non-small-
cell lung carcinoma (NSCLC) is PANDAR. Decreased expression of 
PANDAR correlates with higher overall mortality in NSCLC patients. 
Overexpression of PANDAR could inhibit the proliferation of NSCLC 
cells by inducing apoptosis via targeting p53 (251). 
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There are many other lncRNAs, account for possessing a tumor suppressor 
role. For example, GAS5 lncRNA low expression was shown to strongly 
correlate with gastric cancer metastasis and unfavorable outcome. The 
overexpression of GAS5 represses gastric cancer cell invasion and 
migration through stabilizing p53 (252). 
Oncogenic LncRNAs  
Besides the tumor suppressor lncRNAs, there are many lncRNAs whose 
de-regulation can promote cell growth and metastasis in different types of 
cancers; they are described as oncogenic lncRNAs. 
The metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), 
also known as NEAT2, is a well-investigated highly conserved oncogenic 
lncRNA. MALATI knock out mice develop normally and suggesting 
MALAT1 is not essential for early development (253). Depletion of 
MALAT1 showed a reduction in cell proliferation and tumor progression 
in breast cancer cells (254). MALAT1 induces EMT transition switch via 
the PI3K/AKT pathway in epithelial ovarian cancer (EOC) (255). Overall 
these studies indicate the oncogenic role of MALAT1 and raise a possibility 
that MALAT1 inhibition as therapeutic option. 
LncRNA HOTAIR also possesses oncogenic characteristics like promoting 
invasion and metastasis, showed in different cancers by recruiting PRC2 
or chromatin modifications (226). Interestingly in lung adenocarcinoma, 
HOTAIR was reported to contribute to chemoresistance to cisplatin 
treatment (256). Consistently in another study, HOTAIR expression was 
reported to be correlated with cisplatin resistance in NSCLC (257).  
NORAD lncRNA is a crucial part of the DNA damage response (DDR) 
pathway and responsible for regulating chromosomal instability (258). In 
CRC tissues, esophageal squamous cell carcinoma (ESCC) and bladder 
cancer, the overexpression of NORAD have been found to contribute to 
tumor progression, hence serve as another oncogenic lncRNA (259, 260). 
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1.2.8 lncRNA as a disease biomarker 
The lncRNAs are becoming promising as biomarkers for different 
diseases. As I have discussed above, diverse lncRNAs possess oncogenic 
or tumor suppressor roles, therefore, they could be used as biomarkers for 
disease diagnosis and for planning further therapeutic strategy, but further 
research is necessary. Though presently there are limited reports about 
lncRNAs which are regularly used as a validated biomarker for disease, I 
would like to discuss some of the few lncRNAs with a promise to develop 
into biomarkers for disease progression. The lncRNA PCAT1 expression 
in the prostate cancer patient can be used to predict the disease outcome 
where higher expression of PCAT1 correlates with aggressive disease 
suggesting this could develop as lncRNA biomarker (192). Interestingly, 
the lncRNA DD3, later named as prostate cancer antigen 3 (PCA3) acts as 
another specific prognostic biomarker in prostate cancer and can be 
detected in urine samples (261). MALAT1 lncRNA has been used as a 
biomarker and detected in liquid biopsy of NSCLCs patients and also in 
Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens. MALAT1 
expression correlates with metastasis and EMT in NSCLC (195, 262, 263). 
In CRC tumor tissues as well, MALAT1 serves as a potential predictor for 
tumor metastasis and prognosis symptoms (264, 265).  
 
 
Sanhita Mitra 
33 
lncRNAs Cancer types Interactive 
protein 
partners 
Functional roles Reference  
      
HOTAIR 
Oncogenic 
 
 
 
MALAT1 
Oncogenic 
 
 
NORAD 
Oncogenic 
 
 
 
HOTTIP 
Oncogenic 
 
 
PCAT1 
Oncogenic 
 
 
 
MEG3 
Tumor 
suppressor 
 
LincRNA-
P21 
Tumor 
suppressor 
 
PANDAR 
Tumor 
suppressor 
 
GAS5 
Tumor 
suppressor 
 
CASC15-S 
Tumor 
suppressor 
 
Breast, CRC, 
gastric, lung, 
prostate 
cancer 
 
Lung, EOC,CRC, 
breast cancer 
 
 
CRC, ESCC, 
bladder cancer 
 
 
 
HCC 
 
 
 
Prostate, CRC, 
HCC and 
gastric cancer. 
 
 
Cervical, 
bladder 
cancer, HCC  
 
Lung, DLBCL, 
CRC 
 
 
 
NSCLC 
 
 
 
Gastric cancer 
 
 
 
 
Neuroblastoma 
PRC2 
 
 
 
 
SFPQ 
 
 
 
PUMILIO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HnRNP-K 
 
 
 
 
 
 
 
 
Glucocortic-oid 
receptor 
Chromatin remodeling, 
promote migration, invasion 
and metastasis and up-
regulated in tumors. 
 
Promote tumor growth and 
metastasis, correlated with 
poor survival. 
 
Regulation of genomic 
stability. Up-regulated in 
tumors and contributes to 
tumorigenicity. 
 
Upregulated in tumors along 
with HOXA13, associated with 
metastasis and survival. 
 
High expression in tumors 
related to poor survival, 
migration, invasion, and 
metastasis. 
 
Inhibition of tumor growth, 
cell proliferation, invasion and 
migration. Induce apoptosis. 
 
Induce p53 mediated 
apoptosis. Reduction of cell 
proliferation, cell cycle 
progression & survival. 
 
Inhibit proliferation, induce 
apoptosis via targeting p53 
 
Repression of cell invasion 
and migration through 
stabilizing p53. Titrate 
glucocorticoid receptors 
away from target genes. 
 
Induce neural growth and 
differentiation and 
suppression of tumor growth. 
(226),(256), (257) 
 
 
 
 
(264), (253),(255) 
(254), 
 
 
(266),(258),(259),(260) 
 
 
 
 
(267) 
 
 
 
(268) 
 
 
 
 
(243),(244),(245) 
 
 
 
(227),(248),(249) 
 
 
 
 
(251) 
 
 
(252), (220) 
 
 
 
 
 
(279) 
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Table 1. The list of regulatory lncRNAs in cancer and their interactive protein partners and 
functional roles. 
1.3 Long non-coding RNA – the rising 
player of neuroblastoma 
Regardless of increased knowledge about NB, still we lack information on how 
different factors contribute to the high-risk NB disease progression. Also most 
importantly despite advancement in multi-disciplinary treatments for treating 
high-risk NB, the average percentage of patient survival is just 50% (269). This 
necessitates identifying the novel players and biomarkers to stratify the risk of 
NB and understanding the biology of NB disease progression in a better way. 
The lncRNAs have begun to be illuminated as a contributor to NB along with 
their role in different other cancers, in recent years. The deeper understanding 
of the regulatory mechanisms contribute in lncRNAs mediated NB tumor 
pathogenesis can provide novel perspective to the high-risk NB patient 
prognosis and future treatment strategies.  
T-UCRs 
Transcribed ultra-conserved regions (T-UCRs) are a group of lncRNAs which 
is 100% conserved between human, rat and mouse genomes. 481 T-UCRs were 
reported in a study by Bejarno et al in 2004 (270) and later these 481 T-UCRs 
found to be aberrantly expressed in human leukemia and other carcinomas 
(271). These observations were then taken forward to evaluate the role of T-
UCRs in NB progression. Scaruffi et al (272) demonstrated that the 
upregulation of 15 T-UCRs was able to distinguish the survival outcome of the 
patients and predict the event-free survival (EFS) and overall survival (OS) in 
high-risk NB. 7 T-UCRs of the total 481 investigated T-UCRs were found to 
be overexpressed in MYCN amplified tumors and 3 of these lncRNAs were 
upregulated upon MYCN induction. The T-UCRs lncRNAs are linked with 
carcinogenic pathways, for example, cell cycle, replication, DNA repair, cell 
proliferation, differentiation and apoptosis. (273). Interestingly in a recent 
study 32 out of 481 T-UCRs were noted to show differential expression with 
retinoic acid (RA) induced neural differentiation (274). Downregulation of T-
UC.300A, which is one of the 32 differentially expressed T-UCRs, was able to 
decline the proliferation and invasion in NB tumors. Functional analysis of 
other differentially expressed T-UCRs in NB tumors leave scope for a better 
understanding the importance and significance of T-UCRs in NB pathogenesis. 
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ncRAN  
Yu et al first identified ncRAN lncRNA, which is differentially expressed in 
high-risk NB patients with 17q gain using cDNA microarray with 136 NB 
tumors (275). As 17q gain is the most frequent genetic alteration reported in 
NB and associated with a poor outcome (276), its transcriptional outputs need 
to be studied further, it may have role in determining disease phenotype. 
ncRAN lncRNA possesses an oncogenic property, as the overexpression of 
ncRAN is correlated with the aggressiveness of the high-risk NB (277). Though 
the mechanistic and functional role of ncRAN still needs to be investigated, this 
finding opens up the importance of analyzing the role of lncRNA transcripts 
that harbor in the chromosomal gain/loss regions related to NB stratification.    
lncUSMycN 
Recently Liu and colleagues reported a lncRNA lncUSMycN, which is 
located 14 kilobases upstream of the MYCN gene and maps to the 
frequently amplified chromosome 2p region. lncUSMycN is often co-
amplified and overexpressed with the 130-kb amplicon containing MYCN 
in MYCN amplified NB cell line and its overexpression negatively 
correlates with patient overall and event-free survival. The transient/stable 
knockdown of lncUSMycN leads to decreased MYCN mRNA and its 
protein as well. lncUSMycN has an important role in MYCN RNA 
upregulation and cell proliferation in NB cells by interacting with its 
functional protein co-partner Nono, an RNA binding protein (278).  
6p22 locus derived lncRNAs 
Chromosome 6p22 locus harbors NB risk associated SNP, rs6939340 
where homozygous condition for ‘G’ allele is associated with aggressive 
NB (85). The SNP is located in the intronic region of two lncRNAs, 
NBAT1 (neuroblastoma associated transcript1, LOC729177 or CASC14) 
and LINC00340 (CASC15). These two lncRNAs’ transcriptional activity 
correlates with the polymorphism rs6939340, which overlap with a 
putative enhancer. Both of the lncRNAs possess a tumor suppressor role 
in NB, which will be described in detail in this thesis. Another transcript 
of 6p22 locus is CASC15-S, which shares the promoter with NBAT1 but 
transcribes in opposite direction, also act as a tumor suppressor for NB 
(279) . Any significant correlation was lacking between the risk genotype 
(rs6939340) and the CASC15-S transcript expression as verified by 
expression quantitative trait loci (eQTL) analysis (279). To address this 
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shortcoming orthogonal methodologies have been used by this study to 
fine map more SNPs which are associated with the 6p22 locus and 
identified another SNP which mapped to rs9295534, overlapped with an 
enhancer, located upstream of CASC15-S. Interestingly rs9295534 risk 
allele disrupts the enhancer function. Further, it has been shown the low 
expression of CASC15-S is associated with more aggressive NB by 
inducing proliferation and invasiveness of NB cells and substantial 
suppression of differentiation- specific proneural gene signatures that lead 
to decreased overall survival probability in NB (279). 
Paupar  
Another highly conserved lncRNA is Paupar, which is identified as a 
differentially expressed lncRNA transcript during mouse neuronal 
differentiation using N2A NB cells. Paupar controls a complex 
transcriptional network; in cis, it regulates expression of upstream gene 
Pax6, which is a known neural transcription factor. In trans regulation, 
Paupar regulates genes located on different chromosomes as well. Paupar 
knock-down disrupts the cell cycle profile and induces differentiation of 
N2A cells (280). 
Other NB associated lncRNAs 
In recent years, many other lncRNAs have been reported to have a 
significant role in NB disease progression. Six MYCN regulated lncRNAs 
were identified using a non-coding RNA microarray based screen and were 
characterized for their functional role in NB pathogenesis (281). 
Luciferase and ChIP assays demonstrated MYCN represses the promoter 
activity of linc00467, one of the six MYCN dependent lncRNAs, by 
directly binding to the promoter of linc00467. Further downregulation of 
linc00467 led to reduced cell viability and elevated apoptosis via activating 
the tumor suppressor gene DKK1 in NB cells. Apart from regulating 
lncRNA expression by direct binding, MYCN can also regulate lncRNA 
expression via activation of chromatin remodeling genes. It was reported 
in a recent study that MYCN activates MALAT1 lncRNA via modulating 
the expression of its direct target genes JMJD1A, which is an H3K9-
specific histone demethylase (282). Elevated MYCN expression was 
thought to induce higher JMJD1A levels and which in turn activates 
MALAT1 by histone H3K9me3 demethylation at the MALAT1 gene 
promoter. Moreover, it has been shown MALAT1 can induce cell 
proliferation, cell invasion and cell migration of NB cell lines. JMJD1A 
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inhibitor DMOG treatment in NB cell lines demonstrates that MYCN 
target genes can be potential therapeutic option for NB treatment. 
The higher expression of another lncRNA SNHG16 was found to be 
positively associated with poor clinical outcomes and additionally 
silencing of this transcript leads to inhibition of cell proliferation and 
migration, and induced cell cycle arrest at the G0/G1 phase in NB 
SH-SY5Y cells (283).  
RNA-seq analysis of MIAT lncRNA knockdown NB and glioblastoma 
cells reveals its oncogenic role and further characterization of MIAT 
function indicates that knockdown of MIAT can reduce survival and cell 
migration and promote basal apoptosis (284). 
LncRNA KCNQ1OT1 has been shown to induce apoptosis in NB cells by 
sponging the miR-296-5p so that it cannot bind to 3'UTR of its target 
apoptotic marker Bax (285). 
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2 AIM 
The main objectives of the current thesis was to understand the role of long 
non-coding RNAs in pediatric cancer neuroblastoma (NB) development and 
progression. In all three papers of this thesis, we used NB risk-associated 6p22 
locus as our model system to understand the specific roles of 6p22 locus 
derived lncRNAs in NB development and progression.  
Paper I 
 Identification of differentially expressed lncRNAs between 
low- and high-risk NB tumors. 
 To functionally characterize the identified NB associated 
transcript 1 (NBATI) as a biomarker that could predict clinical 
outcome of NB.  
Paper II 
 Identification and functional characterization of CASC15 as 
tumor suppressor lncRNA derived from 6p22 in NB. 
 To characterize the protein partners of 6p22 derived lncRNAs 
that are involved in NB pathogenesis. 
 To explain the functional regulatory axis of 6p22 derived 
lncRNAs which maintain an undifferentiated state in NB 
cells. 
 Paper III 
 Identification of NBAT1 lncRNA as a p53 responsive 
lncRNA which can regulate p53 subcellular localization. 
 To understand the mechanism, how NBAT1 lncRNA 
determines the genotoxic drug resistance in NB cells. 
 Identification of a potential therapeutic approach for high-risk 
NB with defective p53 cellular localization. 
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3 MATERIALS AND METHODS 
 
Patient and Tumor Material 
 
The primary NB tumors were collected from surgery followed by a snap freeze 
and storing at -70° C for further analysis. In Paper I a set of 15 tumors we 
selected and extracted RNA from these tumors were sequenced - three low-
risk tumors with numerical only genotype and 12 high-risk tumors with both 
11q deletion (n = 6) & MYCN-amplification (n = 6).  We used two cohorts of 
NB patients for further analysis in paper I. In cohort I, there were 106 Swedish 
and 2 German patients with ethical permit number (Dnr 2011/354), approved 
by Regional Ethical Review Board, Uppsala University, Uppsala. Cohort II 
consists of 498 patients and RNA-seq data from this cohort has been used 
(NB2004, 04-049; NB97, 9764; an ethical committee of the Medical Faculty 
of the University of Cologne).  In Paper II along with cohort II, we extended 
the RNA-seq data from 59 Swedish patients who are part of cohort I. 
 
Cell culture and differentiation  
The human NB cell lines we used are SH-SY5Y, IMR32, SK-N-BE(2), SK-N-
AS, SK-N-DZ, SK-N-F1, Kelly and SHEP for our studies and all of them were 
maintained in 37°C with 5% carbon dioxide. Dulbecco’s modified Eagle’s 
medium (DMEM) media supplemented with 10% fetal bovine serum (FBS) 
and antibiotics were used for culturing SH-SY5Y, SK-N-BE(2), SK-N-AS, 
SK-N-DZ, SK-N-F1 cell lines. For the IMR32 cell line, EMEM media 
supplemented with 10% FBS, 1% Glutamax, 1% Sodium pyruvate, 1% non-
essential amino acids and antibiotics were used. SHEP and Kelly cell lines 
were cultured in RPMI media supplemented with 10% FBS, 1% glutamax and 
antibiotics.  
For differentiation of SH-SY5Y cells, cells were seeded in a density of 60,000 
cells/ml using ‘pre-differentiation media’ which is Dulbecco’s modified 
Eagle’s medium with F12 medium (1:1) (Gibco) supplemented with 10% heat-
inactivated FBS, 2mM L-glutamine and antibiotics, 24h prior to differentiation 
induction. After 24 h, differentiation was induced by adding 10 mM all-trans 
retinoic acid (ATRA/RA, Sigma) along with “Differentiation medium” which 
is 1:1 mix of DMEM and F12 medium supplemented with only 1 % heat-
inactivated FBS, 2 mM L-glutamine and antibiotic. Cells were supplied with 
fresh differentiation medium with RA every 3 days of the differentiation 
process. Cells were collected at desired time points. SK-N-BE(2), SK-N-AS, 
IMR32 cells were also differentiated. These cells were plated in their 
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respective  culture media containing 10 % FBS, 1% glutamax and antibiotic in 
a density of 60,000 cells/ml and after 24 hours, differentiation media which is 
their respective culture media with 1% FBS, 1% Glutamax and antibiotic was 
added along with 10 mM RA to induce differentiation. Differentiation media 
containing 10 mM RA was changed every third day.  
 
Immunofluorescence 
 
NB cells were seeded on the glass coverslips, placed into the 24 well cell 
culture plate in a density of 50,000 to 60,000 cells/ml for differentiation 
experiments (paper I & paper II) and in a density of 140,000 cells/ml for 
genotoxic drug treatments followed by immunostaining experiments (paper 
III). Cells were incubated for 24 hours and attached to the coverslip. After 24h, 
the desired treatments has been started and at the different chosen time points 
cells on the coverslips were fixed for 15 minutes with  3.7% formaldehyde 
followed by 5 min washes (3 times) with phosphate-buffered saline (PBS). 
Next cells were permeabilized for 10 min with PBS containing 0.25% Triton 
X-100 (PBST) followed by 5 min washes (3 times) with PBS. Then using 1% 
Bovine Serum Albumin (BSA) in PBST, blocking was performed for 30 
minutes. The slides were incubated with desired primary antibodies such as 
Tau (136400, Invitrogen), Tyrosine-hydroxylase (TH) (P21962, Invitrogen), 
p53 antibody (Millipore, 05-224), CRM1 antibody (CST, 46249S) for 1 hour 
at room temperate followed by 5 min washes (3 times) with PBS. Next 
coverslips were incubated with respective fluorescent tagged secondary 
antibodies for 1 hour at room temperature followed by 5 min washes (3 times) 
with PBS. Then the coverslips were mounted on a slide with DAPI (4',6-
Diamidine-2'-phenylindole dihydrochloride) containing prolong gold anti-fade 
reagent mounting media (1972784, Invitrogen). Slides were kept at 4 ° C until 
microscopic images were taken. 
 
Immunoblot 
 
Proteins were extracted from cultured cells with different treatments, using cell 
extraction buffer (Thermo Fischer Scientific, 1868573A) and complete 
protease inhibitor cocktail (Roche Diagnostics). A brief sonication (for better 
extraction of the chromatin-bound proteins) was performed, followed by 
spinning the lysate down at 13000 rpm for 20 min at 4°C, where the 
supernatant contains the protein of interest. Protein concentrations were 
measured by using the Pierce BCA Protein Assay Kit (Thermo Fischer 
Scientific). Lysates (20-30 mg) were resolved on 4-12% Bis-Tris Gel 
(NuPAGE, Invitrogen) followed by a transfer of proteins to a nitrocellulose 
membrane. Then the nitrocellulose membrane was blocked for 1 hour in 5% 
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skim milk (Cat#70166, SIGMA-ALDRICH) in 1X TBS-T (10 mM Tris-base 
pH 7.5, 150 mM NaCl, and 0.1% Tween) at room temperature. Membranes 
were then incubated with primary antibodies in the same blocking buffer 
against desired proteins in a particular ratio according to manufacturers’ 
protocol for overnight at 4°C followed by 5 minutes (3 times) washes with 1X 
TBS-T. One hour incubation with secondary antibodies, with 5% skim milk 
made in 1X TBS-T was carried out, followed by 5 minutes (3 times) washes 
with 1X TBS-T. Using chemiluminescent Substrate (Cat#34080, Thermo 
Scientific) protein bands were visualized with the help of IMAGE BioRad 4.0 
alpha software.  
 
MTT, migration, invasion assay 
The MTT assay was performed in NB cells with different conditions or after 
genotoxic drug treatments, using the Cell Titer 96 Non-Radioactive Cell 
Proliferation assay kit from Promega (G4000), according to the manufacturer’s 
protocol.  
The migration and invasion assay was performed with the help of biocoat 
invasion chamber (BD bioscience, 354480) following the manufacturer’s 
instructions. In brief, cells were seeded in a density of 50,000-60,000 cells/ml 
in the upper chamber of the biocoat invasion chamber in respective media with 
1 % serum (FBS) and the lower chamber was provided with 10 % FBS media 
which allow cells to migrate from the upper chamber to the lower chamber of 
the biocoat invasion chamber and then migrated cells were stained with 
SNABB-DIFF Kit (Labex AB, Sweden) and were counted under light 
microscopy. 
 
Colony-forming assay (CFU) 
10,000 cells were seeded per well in six well plates and were allowed to grow 
colonies for 10-12 days. Cells were then washed twice with PBS for 5 min 
followed by fixation with 100% Methanol for 5 min at room temperature.10 
minute’s incubation with 1% crystal violet solution was then performed after 
removing the fixation solution. The crystal violet solution was then removed 
and the plates immersed in tap water to carefully rinse off the crystal violet. 
After a short air-drying, images were taken. 
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Chromatin immune precipitation (ChIP) 
Cells were fixed using 1% formaldehyde at RT for 10 minutes. Using 1X nuclei 
isolation buffer (40mM Tris-HCl pH7.5, 20mM MgCl2, 4% tritonX-100, 
1.28M sucrose) nuclei were isolated from the formaldehyde cross-linked cells 
followed by resuspension in lysis buffer (0.1%SDS, 0.5% TritonX 100, 20mM 
Tris-HCl pH7.5, 150mM NaCl) with a ratio of 1ml lysis buffer per 10 million 
of cells. Then cells were sonicated (Bioruptor, around 30 cycles) to get 
chromatin fragments of about 500bp. Immunoprecipitation of chromatin using 
antibodies against the desired proteins was carried out for 4-5 hours at 4°C 
where chromatin was incubated with Protein A magnetic beads followed by 
washing and elution of the chromatin from the beads and then the DNA was 
purified and used for further analysis like ChIP quantitative-PCR. 
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4 RESULTS & DISCUSSION 
4.1 The Risk-Associated Long Noncoding RNA 
NBAT1 Controls Neuroblastoma Progression by 
Regulating Cell Proliferation and Neuronal 
Differentiation. 
 
Neuroblastoma (NB) is an extra-cranial childhood malignancy of the 
sympathetic nervous system and accounts for nearly 6-10% of childhood 
cancers and 15% of cancer death in children. NB tumors are highly 
heterogeneous and depending on their clinical outcome, they can be divided 
into distinct clinical subtypes. Broadly, NBs can be classified into two subtypes 
– high-risk tumors (with MYCN oncogene amplification, 1p, 11q deletion and 
17q gain) that are aggressive and has a high chance of recurrence and show 
unfavorable outcome. On the other hand, the prognostically favorable low-risk 
tumors (only with chromosomal copy number variation) with a high chance of 
regression. We aimed to characterize the mechanisms by which low-risk NB 
tumors undergo spontaneous tumor regression. Towards this main aim, we 
characterized differentially expressed transcripts between high- and low-risk 
NB, by sequencing transcriptomes of low-risk NB tumors and two high-risk 
subtypes; NBs harboring 11q deletion or MYCN amplification. We obtained 
584, 756 and 70 differentially expressed transcripts in the comparisons 
between low-risk vs 11q deletion, MYCN and high-risk tumors respectively. 
We obtained 24 non-annotated lncRNAs from differential expression analysis 
of only lncRNAs between high and low-risk subtypes. We named them Cuff 
1-24 and validated some of their expression in an independent cohort of 23 
primary NB tumors.  Some of these lncRNAs mapped to chromosomal loci 
that have been implicated in oncogenic (MYCN amplified region) and tumor 
suppressor functions (11q and 1p). This suggests that these differentially 
expressed lncRNAs can act as oncogenic or tumor-suppressing genes.  We also 
did a mutational screening analysis of differentially expressed genes and found 
that 27.4% of them carried somatically acquired mutation or insertion and 
deletion. 
We identified an annotated but uncharacterized lncRNA LOC729177, which 
showed differential expression between high and low-risk tumors, and we 
named this RNA NBAT1 (NB associated transcript-1). We validated the 
expression of NBAT1 in an independent cohort of 93 NB patients using qRT 
PCR analysis, and in RNA-seq data obtained from another independent clinical 
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cohort of 498 NB tumors. NBAT1 is expressed at a lower level in high-risk 
tumors than low- risk tumors and its decreased expression correlates with poor 
prognosis in NB patients. We performed the multivariate Cox regression 
analysis on a large cohort of patients (n=498) and the result suggests that 
NBAT1 can act as an independent prognostic marker for predicting event-free 
survival in NB patients. We also observed that a known high-risk associated 
SNP rs6939340 resides in the intron of NBAT1 on chromosome 6p22. To 
investigate if there is any functional connection between NB risk associated 
SNP and NBAT1 expression, we sequenced NB patients’ genomic DNA from 
51 high-risk primary tumors over the SNP and found that G/G genotype is 
associated with lower NBAT1 expression in high-risk tumors. By analyzing 
DNA methylation of 5 CpG sites flanking the NBAT1 promoter, we showed 
that the NBAT1 promoter was hyper-methylated in the high-risk NBs and 
under-methylated in low-risk NBs. These observations collectively indicate 
that both CpG methylation at the NBAT1 promoter and the high-risk NB-
associated SNP rs6939340 functionally contribute to the differential 
expression of NBAT1. 
To understand the functional role of NBAT1 in NB disease development, we 
downregulated NBAT1 lncRNA in the SH-SY5Y cell line using siRNAs or sh-
RNA. We found that the downregulation of NBAT1 resulted in increased cell 
proliferation and migration in SH-SY5Y cells, which is consistent with NBAT1 
tumor suppressor properties. To identify the putative targets of NBAT1, we 
sequenced total RNA obtained from control, NBAT1 depleted, and we found 
1348 differentially expressed genes. Biological pathway analysis of the 
differentially expressed genes revealed that enrichment of biological processes 
such as cell migration, proliferation, neuronal differentiation, and nervous 
system development. To understand the significance of NBAT1 target genes in 
NBAT1 mediated cell proliferation and migration, we chose genes such as 
SOX9, VCAN, and OSMR with oncogenic properties. Downregulation of these 
genes in the NBAT1 depleted cells reversed the high proliferative and invasive 
properties of NBAT1 depleted cells. 
We then addressed the mechanisms underlying the NBAT1 dependent 
suppression of genes involved in oncogenic pathways. To this end, we 
performed RNA immunoprecipitation assay (RIP) using the EZH2 antibody 
and found that EZH2 specifically interacts with NBAT1. EZH2 is a member of 
the PRC2 complex, which is required for the maintenance of repressive mark 
H3K27me3. To further understand the functional connection between NBAT1 
and EZH2, we sequenced total RNA from NBAT1 and EZH2 depleted SH-
SY5Y cells and found a significant overlap of genes implicated in cell 
proliferation and cell migration. Interestingly, a large portion of the overlapped 
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genes was enriched with H3K27me3 modification and this repressive 
modification at the NBAT1/EZH2 target gene promoters was lost upon NBAT1 
downregulation. These results indicating that NBAT1/EZH2 functional 
interaction is critical for the repression of genes implicated cell proliferation 
and migration.  
As we found neuronal differentiation as one of the top biological processes that 
are disturbed following NBAT1 knockdown, we investigated the role of NBAT1 
in neuronal differentiation in SH-SY5Y cells. SH-SY5Y cells represent 
undifferentiated neural progenitors and they differentiate into neuronal cell 
types upon treatment with retinoic acid. We observed that NBAT1 is 
significantly upregulated during retinoic acid (RA) induced neuronal 
differentiation of SH-SY5Y cells and its downregulation resulted in perturbed 
neuronal differentiation. Ectopic expression of NBAT1 in NB cell lines with 
poor differentiation capacity such as SK-N-BE (2) and SK-N-AS, representing 
high-risk tumors, led to increased neuronal differentiation, and this observation 
is consistent with the pro-differentiation property of NBAT1.  
We were next interested in investigating the reasons underlying the 
downregulation of neuronal lineage-specific genes upon NBAT1 knockdown. 
We found that a neuronal-specific silencing factor NRSF/ REST, which 
represses the neuronal genes’ expressions in non-neuronal tissues and 
embryonic stem cells, was upregulated following NBAT1 depletion. We also 
found that this gene has an increased expression in MNA tumors in comparison 
to the non-MNA tumors in the R2 data set (A genomic analysis and 
visualization platform). Therefore, we sought to identify the connection 
between NRSF/REST and NBAT1 during the neuronal differentiation of NB 
cells. Depletion of REST in the NBAT1 knockdown SH-SY5Y cells, rescued 
the neuronal phenotype, indicating that NBAT1 may control neuronal 
commitment via repressing the NRSF/REST pathway. 
In summary, this study has identified several high-risk or low-risk NB specific 
lncRNAs, which could serve as potential biomarkers for disease assessment. 
Besides, our study has identified a novel NB-specific lncRNA NBAT1, whose 
higher expression predicts a good prognosis, and importantly, it acts as 
independent prognostic marker of event-free survival.  Our functional 
investigations revealed that NBAT1 is a tumor suppressor. It inhibits cell 
proliferation and migration by epigenetically repressing oncogenes and 
promotes neuronal differentiation via repressing NRSF/REST pathway (Figure 
5).  
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Figure 5. Proposed model explaining the tumor suppressor and neuronal differentiation 
properties of NBAT1. NBAT1 controls tumor progression by suppressing tumor-specific 
genes such as SOX9, VCAN, and OSMR via regulating chromatin structure epigenetically. 
On the other hand, high expression of NBAT1 promotes neuronal lineage commitment by 
suppressing NRSF/REST gene. Adapted from Pandey GK, Mitra S et al; Cancer Cell; 
2014; 26(5):722-37. 
 
4.2 Sense-Antisense lncRNA Pair Encoded by 
Locus 6p22.3 Determines Neuroblastoma 
Susceptibility via the USP36-CHD7-SOX9 
Regulatory Axis 
Genome-wide association studies identified disease-associated SNPs but the 
role of such associations in the disease context has not been well understood. 
In many instances, the disease-associated SNPs overlap with lncRNA loci but 
again the functional connection between such SNP associated lncRNAs and 
disease has not been investigated in detail. Several SNPs located on the 6p22 
locus are associated with aggressive NB and these SNPs overlap with 6p22 
derived lncRNAs. In this paper II, we attempted to explore the role of 6p22 
derived lncRNAs in NB pathogenesis. 
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In Paper I, we have characterized the role of 6p22 derived lncRNA NBAT1 in 
NB pathogenesis. We have shown that NBAT1 is expressed at a low level in 
high-risk tumor and this promotes the proliferation of the NB cells as well as 
prevents their differentiation. The 6p22 locus also contains another lncRNA 
named CASC15 which is a sense partner to the antisense lncRNA NBAT1. 
CASC15 lncRNA has 6 major isoforms CASC15-001 to CASC15-006.  
Analysis of the RNA-seq data from 59 NB tumors from a Swedish cohort 
revealed that both CASC15 and NBAT1 expression is downregulated in high-
risk NBs. Genotyping of 39 NB tumors for an SNP: rs6939340, associated with 
aggressive NB, revealed that CASC15 and NBAT1 transcripts were expressed 
at lower level in tumors with homozygous for the risk allele G (G/G) compared 
to the tumors homozygous for the non-risk allele (A/A) or heterozygous (A/G) 
allele, suggesting that the risk genotype (G/G) contributes to lower expression 
of 6p22 derived lncRNAs. Kaplan-Meier (KM) analysis revealed that CASC15 
lower expression predicts poor overall (OS) and event-free (EFS) survival in 
both the Swedish and German cohorts of NB tumors. Next, we wanted to 
explore in detail the role of different CASC15 isoforms in NB disease 
development and progression.  To address this, we analyzed RNA-seq data 
from 498 tumor dataset and found that among the CASC15 isoforms, CASC15-
003 and CASC15-004 were widely expressed and showed significant 
association with NB-specific clinical features such as age, risk (high/low) and 
MYCN status. In addition, higher expression of both CASC15-003 and 
CASC15-004 could predict good prognosis, suggesting that 6p22 locus derived 
lncRNAs harbor tumor suppressor functions. Consistent with this observation 
depletion of the CASC15-003 and CASC15-004 in SH-SY5Y cells resulted in 
increased cell proliferation, cell migration, and invasion property but the effect 
of the knockdown was more pronounced in the case of CASC15-003 compared 
to CASC15-004. Consistent with in vitro cell culture data, xenografts derived 
from CASC15-003 depleted cells, but not CASC15-004 cells, had increased 
tumor growth. Furthermore, Gene Ontology (GO) analyses of transcriptomes 
of CASC15-003 and CASC15-004 depleted cells also revealed enrichment of 
biological pathways associated with tumor development and progression.  
Next, we wanted to investigate if CASC15 isoforms have any role in the 
neuronal differentiation of NB cells. The expression of CASC15 isoforms was 
upregulated during RA mediated differentiation of NB cells. We observed that 
depletion of both the CASC15 isoforms lead to perturbation in the neuronal 
differentiation but the effect was more evident in CASC15-003 depleted cells 
compared to CASC15-004. To further reconfirm the role of CASC15-003 in 
neuronal differentiation we deleted the CASC15-003 promoter using CRISPR-
Cas9. We obtained cells with heterozygous CASC15-003 promoter deletions 
with a 40 to 60 % decrease in CASC15-003 expression. These cells showed 
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perturbed neuronal differentiation following RA treatment. Gene expression 
analysis revealed that genes related to neuronal differentiation and stem cell 
maintenance were deregulated in CASC15 isoforms depleted cells. 
In paper 1, we observed that the 6p22 locus derived NBAT1 was critical for the 
differentiation of NB cells. Like NBAT1, CASC15 isoforms, also derived from 
the 6p22 locus, have similar functions in neuronal differentiation, indicate that 
NBAT1 and CASC15 isoforms may functionally cooperate with each other to 
regulate the differentiation of NB cells. To identify genes that are critical for 
the neuronal differentiation phenotype, we performed a network analysis with 
deregulated genes after CASC15-003 depletion. The gene network was 
enriched with pathways related to neural crest development and differentiation, 
stem cell maintenance and differentiation. This network included some critical 
NB associated genes like PHOX2B, SOX11, and SOX9. We compared the 
expression pattern of these key network genes in CASC15-003 and NBAT1 
knockdown cells and found that the network genes showed similar expression 
patterns. These data indicate that CASC15-003 and NBAT1 may regulate 
common pathways associated with neuronal differentiation. This prompted us 
to check if these lncRNAs can functionally complement each other. To do so 
we overexpressed NBAT1 lncRNA in the CASC15-003 depleted cells and vice 
versa and found that both the lncRNAs were able to rescue the differentiation 
phenotype in the corresponding cell types suggesting CASC15-003 and NBAT1 
can functionally complement each other for neuronal differentiation. We 
identified SOX9 upregulation in the CASC15-003 and NBAT1 depleted cells as 
one of the key reasons for the lack of differentiation in these cell types and 
knockdown of SOX9 could rescue the differentiation phenotype perturbed in 
CASC15-003 and NBAT1 depleted cells. 
Next, we wanted to investigate the reason behind the upregulation of SOX9 in 
the 6p22lncRNA depleted cells. To this end, we found that the expression of 
chromodomain helicase DNA binding protein 7 (CHD7), a known regulator of 
SOX9 in neural crest cells, was upregulated at the protein level, but not at the 
mRNA level, in the CASC15-003 and NBAT1 depleted cells. Using chromatin 
immunoprecipitation (ChIP) we found that increased binding of CHD7 over 
the SOX9 gene promoter and its distal neural crest enhancer in the lncRNA 
depleted cells, suggesting that higher level of CHD7 in these cells can 
upregulate SOX9 transcription, which is evident in the transcriptomic analysis. 
We identified CASC15-003 and NBAT1 as post-transcriptional regulators of 
CHD7 protein and these two lncRNAs could contribute to determining the 
stability of CHD7 in NB cells. Overexpression of CASC15-003 and NBAT1 in 
NB cells led to a decrease in CHD7 protein stability and an increased level of 
CHD7 ubiquitination.  
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We were then interested in understanding the mechanism(s) by which 
CASC15-003 and NBAT1 regulate CDH7 stability. Chromatin isolation by 
RNA immunoprecipitation (ChIRP) of CASC15-003 in NB cells revealed 
USP36, a deubiquitinase (DUB) enzyme, as one of the interacting partners. We 
validated the USP36 interaction with NBAT1 as well, using ChIRP and RNA 
immunoprecipitation assays. We found USP36 was a regulator of CHD7 
stability in NB cells via modulating the levels of CHD7 ubiquitination. Co-
immunoprecipitation (Co-IP) experiment suggested that they interact 
physically in NB cells and are co-localized in the nucleolus. We next 
investigated how the USP36 association with CASC15-003 and NBAT1 
controls its activity. We observed that USP36, which is preferentially localized 
to the nucleolus in normal cells, gets distributed throughout the nucleus 
following CASC15-003 and NBAT1 overexpression whereas their knockdown 
leads specific accumulation in the nucleolus. Nucleolar-specific localization of 
USP36 occurs via its interaction with nucleolar-specific protein NPM1 and 
overexpression of CASC15-003 and NBAT1 disturbs this interaction leading to 
USP36 distribution throughout the nucleus. Based on these observations, we 
propose that during differentiation of NB cells, upregulation of 6p22 derived 
lncRNAs (CASC15-003 and NBAT1) displace the nucleolar localized USP36, 
thereby affecting USP36 and CDH7 interaction at the nucleolus, and causing 
CDH7 degradation. But in the CASC15-003 and NBAT1 depleted cells USP36 
remains in the nucleolus. This leads to the removal of ubiquitin molecules from 
CHD7 by USP36 DUB activity, and CHD7 protein level therefore remains 
higher during differentiation. The higher levels of the CDH7 in the CASC15-
003 and NBAT1 depleted cells maintain an undifferentiated state of NB cells 
by upregulating SOX9 expression.  
Using locked nucleic acid (LNA) mediated transient knockdown of CASC15-
003 and NBAT1 in NB cells, we have shown that these two lncRNAs act 
synergistically to regulate the differentiation of NB cells and the synergy 
between these lncRNAs was also evident at the level of USP36 cellular 
localization. Overall, these observations in paper II provides a new mode of 
lncRNA function that is the regulation of protein stability via controlling the 
cellular localization of a DUB (Figure 6). 
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Figure 6. The proposed model depicts the role of 6p22lncRNAs during the NB cell 
differentiation through the USP36-SOX9-CHD7 regulatory axis. During the 
undifferentiated state, 6p22lncRNAs show reduced expressions and USP36 localized in the 
nucleolus by interacting with NPM1 through NoLS. CHD7 is co-localized with USP36 in 
the nucleolus and gets de-ubiquitinated and stabilized and leads to SOX9 upregulation to 
maintain the undifferentiated state. On the other hand, during differentiation, 6p22lncRNAs 
get upregulated and USP36 delocalized from the nucleolus as they interact and engaged 
with an elevated level of 6p22lncRNAs that leads to CHD7 ubiquitination and degradation 
and finally lower expression of SOX9, which leads to differentiation. Adapted from Mondal 
T et.al; Cancer Cell; 2018; Mar 12;33(3):417-434.e7.  
4.3 A p53 responsive lncRNA NBAT1 determines 
chemotherapeutic response in neuroblastoma through 
regulating p53 sub-cellular distribution. 
NB has been the most common and therapeutically challenging neoplasm 
during infancy. Despite multimodal therapy, including chemotherapy, 
immunotherapy, surgical removal of tumors followed by radiotherapy, high-
risk NB tumors have a high chance of recurrence. Therefore, advancement in 
terms of prognostication as well as improved therapeutic opportunities is 
necessary for high-risk NBs. p53 is a well-studied tumor suppressor gene, 
involved in suppressing malignancy in a wide range of cancers, by promoting 
cell cycle arrest, DNA damage repair, and apoptosis in response to the cellular 
stress. Inactivation of the p53 transcription factor is a major cause of cancer 
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formation, and approximately, in 60% of all human cancers, p53 inactivation 
is caused by mutations in the p53 gene. Interestingly in NB tumors, p53 is 
rarely mutated, suggesting that p53 inactivation in NB tumors may be 
facilitated by mechanisms other than mutation, like altered intracellular 
localization of p53. Thus, understanding the alternative mechanisms, which 
contribute to p53 functional inactivation in NB, could contribute to developing 
new therapeutic approaches against NB. 
Previously in the paper I of this thesis we identified NBAT1 lncRNA, which is 
encoded from the 6p22, NB hotspot locus. NBAT1 regulates tumor progression 
via its tumor suppressor activity. Low NBAT1 expression is correlated with 
increased NB cell proliferation and poor prognosis. Based on this observation, 
we hypothesized that in high-risk patients, low NBAT1 expression can be a 
causative factor for therapeutic resistance. We investigated in this paper, how 
the low NBAT1 expression contributes to therapeutic resistance in NB tumors. 
We observed that knockdown of NBAT1 in NB cells provides resistance to 
genotoxic drugs whereas overexpression of NBAT1 led to higher sensitivity to 
genotoxic drugs. We found a positive correlation between NBAT1 level and 
sensitivity to MDM2 inhibitor Nutlin-3a treatment across different NB cell 
lines. Using quantitative RT-qPCR we observed that NBAT1 expression was 
activated upon treatments with multiple genotoxic drugs. We verified NBAT1 
upregulation using RNA-seq data after treatment with Nultin-3a in SH-SY5Y 
cells. Loss and gain of function experiments of p53 combined with p53 ChIP-
qPCR demonstrated that NBAT1 is a direct target of p53. Moreover, NBAT1 
activation, due to genotoxic drugs, was also compromised in mutant p53 cell 
lines such as SK-N-AS and SK-N-BE2 cells. Taken together, these data 
indicate that NBAT1 is a bonafide target of p53.  
Gene Set Enrichment Analysis (GSEA) of the RNA-seq data of Nutlin-3a 
treated control and NBAT1 depleted transcriptomes revealed enrichment of 
p53-regulated genes. Expression of well-known p53 regulated genes like p21, 
MDM2 and GADD45A was compromised in Nutlin-3a treated NBAT1 
knockdown cells. This was further supported by ChIP-qPCR experiments 
wherein decreased enrichment of p53 was seen at the promoters in NBAT1 
depleted cells. Interestingly, decreased p53 promoter transcriptional activity 
was observed in p53 promoter controlled reporter constructs as well. These 
observations from the complementary experiments indicated that NBAT1 
depletion affects p53 mediated transcriptional activation under genotoxic drug 
treatments. 
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As NBAT1 depletion affects p53 dependent gene expression and lends 
resistance to genotoxic drugs, the next important question arises how p53 
dependent functions were disturbed in NBAT1 depleted cells. Given the p53 
mutations are rare in NB tumors, we thought that the subcellular localization 
of p53 might have altered in NBAT1 depleted cells. To this end, we analyzed 
the localization of p53 in high- and low-risk NB tumors and we observed that 
in low-risk tumors p53 shows exclusive nuclear localization whereas in high-
risk tumors p53 localization was nuclear-cytoplasmic. Supporting the p53 
localization data in the NB tumor context, NBAT1 depleted SH-SY5Y cells 
also showed preferential cytoplasmic localization compared to control cells. 
We also tested the effect of NBAT1 overexpression on IMR32 cells where p53 
is predominantly localized in the cytoplasm and found that NBAT1 
overexpression led to nuclear accumulation of p53 in IMR32 cells. Even 
ectopically expressed GFP tagged p53 (GFP-p53) was preferentially localized 
in the cytoplasmic compartment in the NBAT1 depleted cells but GFP-p53 
nuclear localization was recovered upon overexpression of NBAT1.  
CRM1 is one of the well-known nuclear exporters, which transports p53 from 
the nucleus to the cytoplasm. We reasoned that altered cellular location of p53 
in NBAT1 depleted cells could be because of the de-regulation of the CRM1 
function. To test this, we treated NBAT1 depleted cells with CRM1 inhibitor 
leptomycin B (LMB) and LMB treatment could recover the nuclear 
localization of p53 in Nutlin-3a treated cells. We also observed that the CRM1 
protein level was higher in NBAT1 depleted cells. During genotoxic stress, p53 
and CRM1 interaction are abolished, as detected by proximity ligation assay 
(PLA). This loss of p53-CRM1 interaction helps in the retention of p53 in the 
nucleus. In NBAT1 depleted cells p53 and CRM1 interaction was still high after 
genotoxic stress, which correlates with cytoplasmic localization of p53. We 
also identified CRM1 is a target of USP36, a de-ubiquitinase (DUB) and 
CRM1 protein level positively correlated with the level of USP36, in NB cells. 
These observations suggesting that the higher CRM1 level in NBAT1 depleted 
cells could be due to lower ubiquitination of CRM1 protein and this high level 
of CRM1 protein is responsible for p53 cytoplasmic localization in these cells 
(Figure 7). 
Further, we used another CRM1 inhibitor Selinexor (KPT-330) which is less 
toxic than LMB. Selinexor alone and in combination with Nutlin-3a could also 
rescue the p53 nuclear localization in NBAT1 depleted SH-SY5Y cells. The 
Selinexor and Nutlin-3a combination was also effective in inducing p53 
nuclear localization in IMR32 cells than the individual drugs alone.  Checking 
of apoptotic markers also indicates that apoptosis was induced more upon 
combination treatments in IMR32 cells.  Interestingly mouse xenograft tumors 
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derived from IMR32 cells when treated with the Selinexor and Nutlin-3a 
combination were more effective in reducing the tumor size compared to 
individual drugs. Taken together we proposed to combine inhibition of CRM1 
and MDM2 could be an effective therapeutic strategy for high-risk NB patients 
with lower NBAT1 expression and cytoplasmic p53 localization. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.The proposed model depicts the mechanism of NBAT1 mediated p53 intra-cellular 
localization upon genotoxic drug treatment and the relation with drug-resistance.  
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5 CONCLUSION  
The published articles and manuscript in this thesis has established the 
following conclusions. 
Paper I 
 We identified a differentially expressed lncRNA NBAT1 
between low- and high- risk NB tumors, which can serve as a 
biomarker for NB risk-assessment. 
 A high-risk NB associated SNP on chromosome 6p22 and 
CpG methylation on NBAT1 are two contributing factors for 
NBAT1 differential expression. 
 NBAT1 depletion causes increase in cellular proliferation and 
invasion via epigenetically silencing of target genes. 
 Loss of NBAT1 affects neuronal differentiation via activating 
NRSF/REST that is a neuronal-specific transcription factor. 
 
Paper II 
 Sense/antisense lncRNA pair - CASC15 and NBAT1 encoded 
from trait-associated 6p22 locus show reduced expression in 
high-risk NB and have a tumor suppressor role. 
 Decreased    expression of the 6p22 derived lncRNAs are 
responsible for maintaining an undifferentiated state by 
regulating a common gene-regulatory network. 
 6p22 locus derived lncRNAs can regulate SOX9 expression 
via modulating USP36 (de-ubiquitinase) cellular localization 
which controls the stability of CHD7. CHD7, a chromatin 
remodeler, binds to SOX9 promoter and distal enhancer to 
induce SOX9 transcription. 
 
Paper III 
 6p22 locus derived tumor suppressor lncRNA NBAT1 is a p53 
responsive lncRNA and has an ability to regulate the sub-
cellular localization of p53. 
 NBAT1 depleted NB cells are resistant against genotoxic 
drugs via p53 cytoplasmic accumulation. 
 In NBAT1 depleted cells CRM1 function is altered and this 
cause the cytoplasmic localization of p53. Cytoplasmic 
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localization of p53 hinders p53 target genes activation during 
genotoxic drug treatment in NBAT1 depleted cells. 
 Inhibition of CRM1 can rescue p53 nuclear localization in 
NBAT1 depleted cells. 
 Combine inhibition of CRM1 and MDM2 was more effective 
in inducing p53 mediated gene expression and apoptosis in 
NB cells with cytoplasmic p53 suggesting this could be a 
possible therapeutic approach for high-risk NB. 
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